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1.1 Second cancer risk after radiation therapy 
Radiation therapy (radiotherapy, RT), an essential component of cancer treatment in more than 
half of all oncological cases, significantly improves patient survival 1-3. The most frequently 
used treatment method in radiation oncology is external beam RT (EBRT), in which high-
energy x-rays, emitted by a clinical linear accelerator (LINAC), specifically hit a target tumor 
volume. EBRT is indeed indispensable as a single treatment method, especially for tumors 
poorly treated by surgery or chemotherapy. Unfortunately, in some cancer survivors, ionizing 
radiation (IR) may promote the development of new, radiation-induced primary malignant 
neoplasms 4. However, not all second-primary tumors, called second cancer (SC), are radiation-
induced. Several non-iatrogenic reasons such as age at first cancer diagnosis, genetic 
susceptibilities to cancer development 5-8, population-specific traits as well as obesity 9 or 
consumption of alcohol 10,11 and tobacco 12,13 can trigger SC. Cancer chemotherapy may also 
promote SC development. For example, a four-fold increased second breast cancer risk have 
been reported in childhood cancer survivors treated with high-dose alkylating agent and 
anthracycline chemotherapy, compared with the general population 14. Nevertheless, an 
increase in SC risk (SCR) in childhood cancer survivors has long been associated with RT used 
as a single treatment modality or in combination with chemotherapy against first cancer 15-19. 
Thus, children with Hodgkin lymphoma (HL) receiving no RT have a substantially lower SCR 
than those treated with RT (5% vs. 25%) 20. Therefore, minimizing the risk of radiation-
associated SC is important, especially for young patients 21. 
According to global cancer statistics, approximately 8% – 18% of all cancer survivors develop 
SC at all 22,23, which is the most common reason for the mortality of first cancer survivors, 
irrespective of gender 24. An analysis of epidemiological studies on adult cancer patients 
estimates that only about 0.67% (3266 of 485481 persons) of all SC cases could be associated 
with radiation after 15 years follow-up of the first cancer treated with RT alone 25. While the 
radiation-related SCR appears to be low in adult cancer survivors, it is expected to be higher in 
long-term survivors of childhood and early adolescence cancer treated with RT 26. Thus, the 
risk for second and continuing new malignancies increases over time in childhood cancer 
survivors, especially for former patients with HL, a disease, which incidence rates peaks in 
children and adolescents 15,19,22,27-32. For example, after 30 years of follow-up, the estimated 
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cumulative incidence of SC among European childhood cancer survivors treated with RT for 
leukemia, HL, and non-HL, was 2.43%, 12.7%, and 2.5% respectively 33. 
Notably, the SCR after RT of HL patients is much higher in long-term survivors of childhood 
diseases than in adults 12,18,34,35. Nevertheless, the advantages of RT in treatment of HL 
outweigh the possible disadvantages of IR. Thus, more than 90% of HL patients are cured 
successfully and their life expectancy increases since year 2000 due to improvements in 
oncology, and particularly in RT, which is often used as a single treatment approach for early 
stage I and II diseases 36-40. 
Since the risk of developing radiation-associated cardiac and pulmonary abnormalities rises 
with increased minimum threshold doses, especially in pediatric HL patients 41, a limited field- 
and dose- RT for thoracic HL treatment recommended, as a reliable risk mitigating solution 42-
46. On the other hand, analysis of long-term complications after HL-therapy showed a doubled 
cumulative mortality due to SC compared to cardiac and other causes 47. 
 
1.2 Radiation dose to volume relationships and SC development 
Since the development of a radiation-induced SC depends on the distribution of the radiation 
dose within the body volumes planned for radiation (irradiated volume), it is associated with 
RT planning and RT delivery technology. Radiation dose describes a quantity of energy 
absorbed per unit of mass expressed by a dose-unit Gray (Gy, Joule ∙ kg−1) named in honor of 
the British physicist and founder of radiobiology, Louis Harold Gray. Thus, the dose 
distribution in RT means how much energy is ultimately absorbed from the irradiated volume. 
The precision of irradiation correlates with better clinical outcome and, therefore, is of great 
importance. Modern RT planning systems enable to perform highly personalized therapy plans 
for each patient individually. Personalized RT today considered as being the most sensible 
strategy for efficient treatment of cancer and protection of normal tissues from undesirable 
radiation dose toxicity. 
The implementation of a three-dimensional- conformal RT (3D-CRT), after the adoption of 
computed tomography (CT) into daily RT practice in the 1990s 48, was a big step towards 
advanced RT. The 3D-CRT techniques shape the radiation beams to include the 3D anatomic 
configuration of the target tissue volume, for precise delivering of therapeutic doses, while 
sparing surrounded normal tissues from undesirable higher doses. During the following years, 
3D-CRT has become increasingly important and continuously developed to a highly conformal 
RT-technique called intensity-modulated radiotherapy (IMRT). IMRT precisely concentrates 
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therapeutic doses to the planning target volume (PTV) and protects healthy (normal) tissues 
from high-dose-toxicity at the expense of increasing the volume receiving low- and moderate- 
radiation doses 49. Its advanced rotational variant volumetric-modulated arc therapy (VMAT) 
covers the PTV with the highest doses in sub-millimeter accuracy while substantially reducing 
unwanted doses to a minimal level by expanding low-dose exposed volume 50-53. Thus, IMRT 
and VMAT generate a so-called “low-dose bath” within the normal tissue while 3D-CRT 
burdens the normal tissue with substantial higher doses due to fewer beam directions. 
A long-standing dogma in radiation oncology postulates that IMRT can increase (almost 
double) SCR compared to conventional 3D-CRT owing to more beam directions and enlarged 
healthy tissue volumes receiving low doses 54-58. Therefore, 3D-CRT has established as a 
conventional technique for the treatment of mediastinal HL, especially for young patients. 
However, which of the two dose-distribution patterns, ‘a little to a lot vs. a lot to a little’ (IMRT 
vs. 3D-CRT), carries the greater risk of SCs remains undecided 46. 
Besides the improvements in modern radiation planning systems, the volumetric accuracy in 
advanced RT has been additionally improved by the implementation of image-guided RT 
(IGRT) 59, such as e. g., in modern RT of prostate cancer 60-63. The image-guidance is performed 
with a low-energy x-ray-based cone-beam CT (CBCT), delivering very low doses to the tissues 
during rotational scanning of the RT-planning body region before a patient receives a next RT 
fraction. The use of specific software matching a CBCT with an irradiation plan results in 
correct patient-couch-position for highly precise irradiation of the target and protection of 
normal tissues. Little is known whether CBCT can increase SCR. However, calculations based 
on the organ absorbed doses estimate an additional 3% to 3.5% increase in SCR when using 25 
to 30 CBCT fractions to the chest 64, probably due to an underlying 3% to 5% increase in 
mutagenic risk 65. It should be noted here that no preclinical study has yet shown the 
disadvantage of additional very lower doses compared to higher doses in terms of the increase 
in SCR. 
 
1.3 Dose-response-relationships for radiation-induced cancer 
The opinion that lower doses may increase the risk of SC compared to high doses, is explained 
by the assumption that irradiated cells may survive the low-grade DNA damage caused by low 
radiation doses, while being killed by high doses 66. Based on this still acceptable assumption, 
established prediction models estimate increased SCR after low compared to high dose 67-74. 
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Because the tumor cells carry substantial genomic alterations and proliferate more rapidly than 
the normal cells, radiation kills tumor cells more efficiently. It is expected that only a part (about 
one-third) of exposed cells could be killed with approximately 2 Gy, which is the most common 
fraction dose in fractionated RT. In more details, this is a highly complex scenario of killing 
and repopulation events of huge cell cohorts along the tracks of radiation paths. The response 
of human cells to a fractionated radiation exposure is therefore determined based on the 
relationship between cell killing and cell repopulation events and is given by the ratio of α/β 
tissue-specific factors, according to the linear-quadratic model 74,75. This model helps to 
determine the therapeutic window for fractionated total doses, as it is described in the manuals 
for radiotherapists 71,76. Furthermore, the mechanistic model for predicting cancer induction 
after fractionated RT bases on the same linear-quadratic response model 77. 
Reflecting the cell repopulation kinetics, the risk prediction models consider an increase in 
dose-response relationship (DRR) for radiation-induced SC after cumulatively received doses 
below 1 Gy, an exponential elevation at a dose range of 1 Gy to 2.5 Gy, and either an increase, 
reaching a plateau or even a decrease at doses above 2.5 Gy 73. However, all of these models 
may contain significant uncertainties in predicting the dose-response relationship at very low 
doses and at very high doses (lower than 0.5 Gy and higher than 10 Gy) because no in vivo 
results exist. Thus, all known SCR models are based on the same and unique epidemiological 
lifespan data of Japanese atomic bomb survivors (ABS) from Hiroshima and Nagasaki 70,78,79. 
However, it is to note that the uncontrolled whole-body exposure of ABS to radiation doses 
lower than 2.5 Gy is not fully comparable to a locally applied fractionated RT performed in 
cancer patients. The whole-body response to low doses of ABS differs additionally from the 
response to local RT doses because the organ-specific sensitivities to the radiation dose, 
determines the risk of radiation carcinogenesis 70. The relative excess risk per Gy among ABS 
at age of 70 years was increased linearly with estimated received dose to the lungs and female 
breast while it was decreased for stomach and thyroid cancers or reached a plateau for rectal, 
pancreatic, colon, bladder, and brain tumors 21. For the exposure to high-dose fractionated local 
RT, a linear increase in relative risk (RR) was associated with breast cancer and brain tumors, 
whereas a plateau estimated for colon, rectal and stomach cancers, and a decrease observed 
only for thyroid and pancreatic tumors 80. Interestingly, evidence for decreased second lung 
cancer risk after lower compared to higher integral dose expositions was recognized in female 
patients treated with whole-breast RT 81. 
Whereas there are some uncertainties in dose-response below 1 Gy in patients treated for their 
childhood cancer with RT alone, certain linearity in the increase of second bone and soft tissue 
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sarcoma incidences were registered after exposure to estimated integral doses of above 10 Gy 
80,82,83. Thus, the results calculated from 28 retrospective studies, including sixteen childhood 
cancer studies, a linear dose-response relationship observed for several SCs developed after HL 
treatment with RT. An exception was second thyroid cancer, showing an increased risk up to 
maximum received dose of about 20 Gy and then either a downturn or an enrichment to a 
plateau at higher doses. The combined risk for all SCs was 5 to 10 times higher for patients 
receiving doses of above 40 Gy, compared with those receiving very low or no radiation doses 
80.  
Most importantly, several retrospective clinical studies indicate secondary sarcomas and 
carcinomas mostly within the PTV or closely adjacent normal tissues exposed to the highest 
doses during RT 84,85. All the dose-response facts mentioned above more likely indicate higher 
toxicity of high doses compared to low doses that contradicts the assumed disadvantages of low 
doses vs. high doses. 
 
1.4 Dose to latency relationships for radiogenic tumor development 
There is reported evidence for association of specific latency times with distinct entities of 
radiation-induced tumors among Japanese ABS who received survivable whole-body doses. 
According to the information of the radiation effects research foundation, the earliest most 
neoplastic disease detected after two to six years of exposure to atomic bomb radiation was 
leukemia. In contrast, an increased risk of solid tumors was not observed during the first decade 
after exposure. However, the increase in incidence rates of solid tumors was discovered in 1956 
first, shortly after the tumor-registries were established in Japan. In a continuing retrospective 
life span study on ABS published in 2003, the relative lifetime-attributable risk of radiation-
associated solid tumors appeared at least four times lower compared to second leukemia, but it 
was still more than five times increased compared to non-exposed populations 86.  
The time from irradiation of a patient to the occurrence of a second malignancy can be 
considered as the latency time to tumor (TTT). There are differences observed between the 
times of occurrence of different SCs in patients who received chemotherapy, RT, or 
‘chemoradiotherapy’ 87. Thus, the prevalent development of second leukemia after 
chemotherapy alone and second solid cancers after RT alone or ‘chemoradiotherapy’ has been 
observed in childhood HL survivors. Therefore, the latency of second solid tumors can certainly 
be associated with expected tumor entities in former RT patients, as shown in the literature 
12,28,34,35,38,88. Accordingly, second lymphomas mostly arise during the first decades of HL 
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follow up, however, relatively earlier than lung carcinomas, to which the approximated TTT 
takes up to two decades. Most solid SCs of esophagus, connective tissue, stomach, thyroid, and 
female breast appear commonly after two to more than three decades of follow up, whereby the 
rate of solid tumors exceeds the rate of leukemia. 
The relationship of RT doses to the latency of radiation-induced different tumors remains 
largely unexplored on an experimental level. 
 
1.5 Characteristics and effects of ionizing radiation 
Ionization means the process of the ejections of electrons from the atoms. There are two main 
types of IR, particle radiation (electrons, protons, α particles, and heavy ions) and 
electromagnetic (photon) radiation (x-rays and γ rays). 
Medical x-rays are produced by the acceleration of electrons in an x-ray tube of a LINAC and 
their deceleration by the collision with the target of gold or tungsten resulting in photon streams 
called ‘bremsstrahlung’ – an original term of x-ray radiation, coined by its discoverer, the 
German engineer Wilhelm Conrad Röntgen in 1895. 
During the generation of x-rays, a fraction of kinetic energy of accelerated fast electrons is 
converted into streams of highly energetic photon packets (quants) with a wavelength ranging 
from 0.01 to 10 nm. The energy of the x-rays is inversely proportional to the wavelength 
expressed by the equation Ex = h ∙ c/λ (where h is Planck’s constant (6.62607015 ∙ 10−34 Joule 
∙ seconds), c is the velocity of light, and λ is the wavelength of radiation. This energy is 
commonly given in electron Volts (eV) so that the x-rays with the wavelength of 0.1 nm have 
the energy of about 124 kilo-electron Volts (keV, 103 eV) while 1 eV = 1.602176638 ∙ 10−19 
Joule. X-rays belong thus a type of IR that can be controlled by choosing the most favorable 
acceleration energies for certain plans. While corpuscular radiation species typically can only 
penetrate about a centimeter deep into the mater, an increase in energy for the acceleration of 
the electrons proportionally increases the depth of maximum doses within the living mater. The 
higher this energy, the deeper the highest dose in the substrate (dose depth). The ability to 
control the dose depth prerequisites the basis for the conformality of photon beam RT. For 
example, x-rays with six Mega-electron Volt (MeV, 106 eV) acceleration energy have an 
approximated maximum dose-depth of about 1.5 cm in water or in the human or animal body. 
A descriptive specification of the penetrating nature of radiation energy is referred to as 
radiation quality – ionization density. A measure of the average energy rate directly transmitted 
along the track of photons or particles per unit distance is defined as linear energy transfer 
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(LET, expressed as keV/µm). The sparsely ionizing x-rays (≈ 0.3 keV/μm), as well as γ-rays 
and electrons, are characterized by a low LET in contrast to densely ionizing high-LET-
radiation types such as e. g. α particles (≈ 100 keV/μm). Therefore, high LET radiation species 
are biologically more effective than low LET radiation. While particles ionize the molecules 
directly, x-rays and γ-rays damage the living matter indirectly, via radiolysis of water and 
generation of H2O
+ interacting with the neighboring water molecule and generating H3O
+ and 
free reactive hydroxyl radicals [OH∙]. Approximately two thirds of the tissue damages irradiated 
with x-rays are caused by indirect actions of photons with water. There are two well-studied 
ionization mechanisms of x-rays known. While the photoelectric effect appears to be relevant 
for radiological low-energy x-rays, the Compton effect, that is the elastic collision of a photon 
with an electron, dominates in RT. This accelerated electron leaves its path and ionizes the 
neighboring atom. Thus, Compton’s effect multiplies the damage of the atoms along the tracks 
of high energetic photons.  
The time scale of radiation effects on the living system comprises three main phases: the 
physical phase of ionization lasting up to approximately 10-18 seconds, followed by a chemical 
phase of the breakage of chemical bonds (10-3 seconds), and a subsequent biological phase from 
DNA repair to the early and late adverse effects lasting from few seconds to many years and 
sometimes even lifelong 71,76. 
The relative biological effectiveness, which is determined experimentally, bases on the effects 
of different types of radiation on the survival rates of different organisms, differs between 
electromagnetic and corpuscular radiation species owing to their specific LET. The 
international atomic energy agency for radiation protection differentiates between deterministic 
(not accidental) and stochastic (random) radiation effects. The deterministic radiation damage 
has a threshold dose below which no damage can expected. After exceeding this threshold, the 
damage increases strongly with increased dose. By contrast, no threshold dose assumed for 
stochastic damage. The most critical adverse effect is radiation carcinogenesis, which is 
dependent on absorbed radiation doses. Thus, radiation protection considered two main dose 
concepts. The organ equivalent dose (organ dose) is defined as an absorbed cumulative dose in 
an organ, multiplied by the specific radiation weighting factors that determine the effectiveness 
of one type of radiation in comparison with reference effects of x-rays and γ-rays (assumed as 
1). The high LET radiation types having a weighting factor of 2 for protons or 20 for the α-
particles and heavy ions. In addition to the equivalent dose, which already involves the 
weighting factors of the different types of radiation, the effective dose also takes into account 
the different sensitivity of the organs and it is calculated by a multiplying the organ equivalent 
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doses with the organ-weighting factors. The international commission on radiological 
protection – ICRP, recommends factor 0.4 for bladder, esophagus, liver and thyroid gland, 0.01 
for the skin, bone surface, brain and salivary glands, and 0.12 for the bone marrow, lungs, 
female breast, stomach, colon and all other organs and tissues that together make 1.0 89. 
Taken together, biological effects of radiation depend on radiation quality, LET, the different 
sensitivity of irradiated organs to doses, temporal dose rate, homogeneity of received doses, 
and so on, but also on factors associated with the individual person.  
 
1.6  Somatic context of radiation carcinogenesis 
Radiation biology provides an understanding of biological mechanisms of the early responses 
of neoplastic and normal tissues such as DNA damage, tumor cell killing and repopulation, 
hypoxia, re-oxygenation but also long-term effects including non-neoplastic adverse alterations 
of normal tissues as well as the development of SCs. 
The highly reactive free radicals damage biomolecules, including DNA, by the uptake of missed 
electrons from affected molecules. DNA is the most important target for radiation-induced 
damage in exposed cells. A radiation dose of about 1 Gy may cause approximately 10000 
ionizations per cell, and consequently about 1000 DNA single-strand breaks and 20 – 40 DNA 
double-strand breaks (DSBs). 
Radiation is also able to induce large deletions and multiple rearrangements within the genome, 
such as several DNA-DNA or DNA-protein cross-links.  
DNA-damage is followed by a biochemical phase of the repair taking approximately 0.5 to 1.5 
hours in most human cells. 
In response to radiation-induced DNA damage, animal cells activate various specific cellular 
mechanisms for the cell cycle-arrest and DNA repair processes. DSBs are the most difficult 
damage for irradiated cells that must be repaired by two alternative mechanisms: a homologous 
recombination repair (HRR) either or a non-homologous end-joining (NHEJ) repair. HRR is 
only available if a homologous allele (sister chromatid) is intact for the use as a template for 
the error-free repair. However, due to the high complexity of radiation-induced chromosome 
aberrations, which increases with increasing radiation doses, mammalian cells preferably use 
the NHEJ repair mechanism which is unable for an error-free repair of processing ends of the 
broken DNA strand. 
Recent radiobiological findings show that in response to radiation-induced DNA damage, an 
exposed cell, either repairs the radiation-damaged DNA, undergoes apoptosis, or retains a 
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mutation and passes it on to progeny. It is believed that radiation-associated cancer is induced 
due to unrepaired or residual DNA-damage in a single exposed cell that proliferates to the clonal 
cell populations. However, several further mutations are required in the cell, to form rapidly 
proliferating aggressive tumor cell populations with persistently increasing genomic instability 
based on the step by step accumulated alterations or completely lost mechanisms such as e.g. 
molecular controlling of cell cycle checkpoints 71,76. 
Mutations occur also spontaneously over time, but radiation may specifically increase the 
likelihood of DNA alterations. However, only specific driver mutations, some of that described 
below, may promote the carcinogenesis, while the silence passenger mutations may not. The 
driver mutations in different genes may predispose humans to the development of tumors, 
including radiation-induced SC. For example, the risk of SC increases with increasing RT doses 
to patients with inactivated tumor suppressor genes Breast Cancer 1 and 2 (BRCA1/2) 6,90,91. 
SCR also increases in breast cancer patients with mutated Ataxia Telangiectasia Mutated (ATM) 
gene 5, acting as a key sensor and signal transducer for DNA-DSB repair 92. Downstream of the 
serine/threonine kinase activity in ATM, a key signal transducer to cell cycle arrest for DNA 
repair is mediated by a transcription factor for several effector genes, the major tumor-
suppressor gene Tumor Protein 53 (TP53) encoding tumor suppressor protein 53 (p53) 93. Loss 
of p53 in tumor cells is a prerequisite for the onset and progression of malignity because of loss 
of cell-cycle regulation and initiation of programed cell death (apoptosis) 94. Hereditary 
heterozygous mutation in one allele of the human TP53 gene causes Li-Fraumeni syndrome 
(LFS), which dramatically increases the risk for spontaneous 95,96 and radiation-induced 97,98 
tumor development. 
Most notably, radiation may promote genome-wide alterations in aggressive second bone 
sarcomas and soft tissue sarcomas in pediatric RT patients 99. The loss of second intact Tp53 
allele in heterozygous mutants, loss of heterozygosity (LOH), have been equally observed in 
many tumor types in humans 98-105, and also in experimental small animals 106-110. Whether the 
aggressiveness of the radiation-induced SC could be specifically shaped by radiation-induced 
Tp53-LOH remained clarified insufficiently. 
 
1.7 Research question and experimental system 
As mentioned previously, there is an experimentally unproven assumption that IMRT will 
increase SCR compared to conventional 3D-CRT in the body volume exposed to low and 
moderate doses, especially in childhood and adolescent cancer survivors. Therefore, radiation 
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physicians are currently advised against IMRT applications for young HL patients who are 
irradiated with the less dose-sparing 3D techniques such as e.g. two opposite anterior-
posterior/posterior-anterior (AP/PA) beam irradiation. However, under consideration of above-
mentioned retrospective data about the relationships of high-doses to SC development, the 
predicted doubling of SCR from low-dose exposure during IMRT may not hold true in clinical 
practice. Moreover, the theory of disadvantages of IMRT owing to enlarged low-dose volume 
compared to 3D-CRT appears less plausible because it was never been confirmed or refuted by 
in vivo experiments. 
A cancer-prone Tp53 functional knockout line of Wistar-rats, established by a target selected 
mutagenesis driven nonsense mutation in the cysteine codon 273 (C273) of the Tp53 gene 108,110-
112, in which the Tp53-mediated tumor-suppression is impaired, seemed to be a suitable 
experimental model for radiation-induced cancer research. In this heterozygous (Tp53+/C273X) 
rat model, the gene defect is not the trigger but an ‘enhancer’ of tumor development, similar to 
the mutation of TP53 in patients with LFS. 
 
1.8 Purpose 
The main purpose of the study was to compare radiation-associated tumor induction after 
mediastinal irradiation with VMAT (rotational IMRT) and AP/PA irradiation in cancer-prone 
Tp53+/C273X rats, simulating mediastinal RT in HL patients. Thus, the study aimed to provide a 
biological rationale to the clinical practice about the justification of withholding IMRT from 
young patients. The main uncertainty – ‘a little to a lot or a lot to a little’ – had to be investigated 
by testing the possible disadvantages of IMRT compared to conventional 3D CRT in rats. 
In order to meet the challenge, the following objectives were pursued: 
 development of a suitable study design and establish the heterozygous Tp53+/C273X rat 
model to demonstrate the development of radiation-induced cancer, 
 comparison of the rates of tumors in rats irradiated with different radiation doses and 
techniques and between the body-volumes exposed to different doses, 
 further analyzes of the life span in differently exposed animal groups and the 
measurements of the TTT from the time point of irradiation, and 
 Determination of the properties of tumors on a pathological and molecular level. 
Thus, this is the first experimental preclinical study of its kind to test the hypothesis of the 
increased carcinogenicity of modern IMRT compared to older 3D-CRT techniques in living 
animals. 
MATERIALS AND METHODS 
12 
2 MATERIALS AND METHODS 
2.1 MATERIALS 
 
2.1.1 Animal husbandry and handling 
 
2.1.2 Radiation delivery and CT  
LINAC Versa HD/Agility MLC Elekta AB, Stockholm, SWE 
Philips Brilliance Big Bore Philips GmbH Market DACH, Hamburg, DE 
Rat standard 1500 cm2 cage Tecniplast, Hohenpeissenberg, DE 
Rat 1500 cm2 IVC cage Tecniplast, Hohenpeissenberg, DE 
SUMC 501 cm2 filter hood IVC Tecniplast, Hohenpeissenberg, DE 
SSNIFF grain-based regular diet SSNIFF Spezialdiäten, Soest, DE 
Rollenpflaster FL TRA 10 m × 2.5 cm Gothaplast, Gotha, DE 
RS-Müllkompressen 5×5 cm, 7.5×7.5 cm TZMO Deutschland, Biesenthal, DE 
F.S.T. Finger Loop Ear Punch (1 mm) Fine Science Tools, Heidelberg, DE 
Small animal isoflurane vaporizer AbbVie Deutschland, Wiesbaden, DE 
Polycarbonate narcosis box with sliding lid Orthopedics laboratory UMM, Mannheim, DE 
Injekt disposable syringes 2 ml, 5 ml B. Braun, Melsungen, DE 
Tuberculin syringes with 0.01 ml graduation Dieckhoff & Ratschow, Longuich, DE 
Neoject cannulas: 22G, 18G, 20G, 25G  Dispomed Witt, Gelnhausen, DE 
CLiP neo safety catheter, 26G (0.6×19 mm) Vygon - Vigmed, Aachen, DE 
Combi stopper PE closing cones  B. Braun, Melsungen, DE 
Luer-lock connector/adaptor, m/m, f/m Shop.lowcostexperiments.de 
PORTEX® PE hose tubes (0.58/0.96 mm) A. Hartenstein, Würzburg, DE 
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SOMATOM force Siemens Healthcare Diagnostics, Eschborn, DE 
Micro-CT Y.FOX YXLON GmbH, Hamburg, DE 
 
2.1.3 Pharmaceuticals and chemicals 
Bepanthen® Augen- und Nasensalbe GP Produktions, Grenzach-Wyhlen, DE 
Isotonic saline solution 0.9% 500 ml B. Braun, Melsungen, DE 
Midazolam-ratiopharm® 15 mg/3 ml Ratiopharm, Ulm, DE 
Domitor® (medetomidin 1 mg/ml) Orion Corporation, Espoo, FIN 
Fentanyl-Janssen® 0.1 mg Janssen-Cilag, Neuss, DE 
Naloxon-Actavis® (naloxon 0.4 mg/ml) Actavis, München-Riem, DE 
Anexate® (flumazenil 0.5 mg/5 ml) Roche Pharma, Grenzach-Wyhlen, DE 
Antisedan® (atipamezol 5 mg/ml) Orion Corporation, Espoo, FIN 
FORENE® (isoflurane 100% V/V) AbbVie Deutschland, Wiesbaden, DE 




LEICA HistoCore Arcadia H Leica Biosystems, Nussloch, DE 
LEICA RM2245 Microtome Leica Biosystems, Nussloch, DE 
LEICA EG 1150 C Leica Biosystems, Nussloch, DE 
LEICA HI1210 Leica Biosystems, Nussloch, DE 
LEICA Autostainer XL Leica Biosystems, Nussloch, DE 
LEICA CM3050 S – Cryostat Leica Biosystems, Nussloch, DE 
Prutscher S/TA/120/1297 Prutscher Laboratory Systems, Neudörfl, DE 
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HERAsafe® KSP12 Thermo Elictron LED, Langenselbold, DE 
Panasonic MDF-DU700VH Freezer PHC Europe, Etten-Leur, NL 
Heraeus® drying cupboard Thermo Scientific Heraeus, Dreieich, DE 
LEICA DMBRE upright light microscope Leica Mikrosysteme, Wetzlar, DE 
Leica DFC 450 Leica Mikrosysteme, Wetzlar, DE 
Supplies: 
MaiMed absorbent pads MaiMed, Neuenkirchen, DE 
30×30 cm Rotilabo®-Presskork-Untersetzer Karl Roth, Karlsruhe, DE 
ROTIPURAN® 37% formaldehyde solution Carl Roth, Karlsruhe, DE 
Dulbecco’s phosphate buffered saline (PBS) Merck KGaA, Darmstadt, DE 
NeoLab Embadding cassettes NeoLab Migge, Heidelberg, DE 
Tissue-Tek® O.C.T.™ Compound Sakura Finetek, Alphen, NL 
Decalcifier soft Carl Roth, Karlsruhe, DE 
Roti®-Histokitt mounting medium Carl Roth, Karlsruhe, DE 
Microscope object slides, 76×26×1 mm Fisher Scientific, Schwerte, DE 
Microscope Cover Glasses 15H 24×50 mm  Fisher Scientific, Schwerte, DE 
FEATHER carbon steel blades C35 Feather safety Razor, Osaka, JPN 
FEATHER stainless steel blades R35 Feather safety Razor, Osaka, JPN 
Sample beakers, with screw cap 100 ml Carl Roth, Karlsruhe, DE 
Fine brushes (#1 and #3) Science Services, München, DE 
Surgical disposable scalpels B. Braun, Melsungen, DE 
Fine scissor - sharp/blunt, 22×900 mm Fine Science Tools, Heidelberg, DE 
Strabismus scissors, 23×115 mm Fine Science Tools, Heidelberg, DE 
Scissors straight, sharp/blunt,14.5 cm Medicon, Tuttlingen, DE 
Tissue forceps - 1×2 teeth, 2×1.5×145 mm Fine Science Tools, Heidelberg, DE 
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Dumont #5 forceps, 0.1×0.06×110 mm  Fine Science Tools, Heidelberg, DE 
Standard pattern forceps 2.8×1.4×130 mm Fine Science Tools, Heidelberg, DE 
Cover Glass forceps, 4×0.6×105 mm Fine Science Tools, Heidelberg, DE 
 
2.1.5 Molecular biology 
Equipment: 
Reference PhysioCare concept pipets Eppendorf, Hamburg, DE 
Agarose gel electrophoresis chamber Biozym, Landgraaf, NL 
OwlTM EC-105 compact power supply Thermo Fisher Scientific, Langenselbold, DE 
INTAS Gel iX20 imager Intas Science Imaging, Gottingen, DE 
Microbalance scale BP301 S  Sartorius, Göttingen, DE 
Accuracy scale LP 620 S Sartorius, Göttingen, DE 
Eppendorf® Bio photometer Eppendorf, Hamburg, DE 
Eppendorf® Thermomixer Compact Eppendorf, Hamburg, DE 
Heraeus Biofuge Pico Heraeus Deutschland, Hanau, DE 
Heraeus MEGAFUGE 8 centrifuge Thermo Fisher Scientific, Langenselbold, DE 
Eppendorf centrifuge 5810 R Eppendorf, Hamburg, DE 
Ice maker machine Manitowoc Deutschland, Herborn, DE 
 
Supplies: 
KAPA Express Extract Kit Merck, Darmstadt, DE 
mi-PCR50 Purification Kit Metabion, Planegg/Steinkirchen, DE 
Rapid PCR Cleanup Enzyme Set New England BioLabs, Frankfurt, DE 
KAPA2GTM Fast PCR Kit VWR International, Darmstadt, DE 
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GoTag®Long PCR Master Mix Promega Deutschland, Mannheim, DE 
GoTaq® colorless PCR Master Mix Promega Deutschland, Mannheim, DE 
2-Log DNA Ladder New England BioLabs, Frankfurt, DE 
Agarose Roti®garose Low Melt Carl Roth, Karlsruhe, DE 
Loading Dye 6× Purple New England BioLabs, Frankfurt, DE 
Gel Red INTAS, Göttingen, DE 
TRIS ≥ 99.9 %;121,14 g/mol Carl Roth, Karlsruhe, DE 
Acetic acid ≥ 95.9 %; 60,05 g/mol Carl Roth, Karlsruhe, DE 
EDTA ≥ 99 %; 292.25 g/mol Carl Roth, Karlsruhe, DE 
LightRun® Barcodes Eurofins GATC Biotech, Konstanz, DE 
 
Primer 
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Tp53/TP53 reference sequences: 
R. norvegicus_strain mixed ch.10, Rnor_6.0_NC_005109.4_8531-9606_bp 
R. norvegicus strain BN chromosome 10 CRA_213000034379661 
R. norvegicus_p53_X2, mRNA_XM_006246595.2 
H. sapiens Tumor Protein 53 (TP53), Ref. Seq. Gene (LRG_321) on chromosome 17, 
NG_017013.2. NCBI GenBank 
 
2.1.6 Software 
Intas capture software INTAS Science Imaging, Göttingen, DE 
A plasmid Editor (ApE); v2.0.49 University of Utah, Salt Lake City, UT, USA 
GraphPad Prism 6.0 GraphPad Software, San Diego, CA, USA 
Monaco® version 5.0 ELEKTA AB, Stockholm, SWE 
MOSAIQ® ELEKTA AB, Stockholm, SWE 
Syngo.via Siemens Healthcare, Erlangen, DE 
RadiAnt DICOM viewer Medixant, Poznan, POL 
Microsoft Office® Microsoft, Redmond, WA, USA 
 
2.1.7 Data repository 
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2.2 METHODS 
2.2.1 Cancer-prone rat model and experimental design 
The experiment was carried out after approval by the regional ethics board 
(Regierungspräsidium Karlsruhe) and following the legal guidelines of the federation of 
european laboratory animal science associations – FELASA. 
Heterozygous Tp53+/C273X rats (Crl:WI(UL)-Tp53m1/Hubr) were kindly provided by colleagues 
from Hubrecht institute for developmental biology and stem cell research, department of 
biomedical genetics, Utrecht, the Netherlands. 

















Schematic overview of work-steps. Heterozygous rats (n = 90), derived from both heterozygous or 
heterozygous and homozygous parents (F1 and F2 respectively) were distributed into the two control 
groups (AN or CBCT only) and four groups for irradiation with different radiation techniques (VMAT 
or AP/PA) and doses (3×5 Gy or 3×8 Gy). Animals were followed up and sacrificed when a solid tumor 
was detectable. The material and data obtained were used to compare tumor rates, latency time to tumors, 
and tumor properties of irradiated and non-irradiated groups of rats and between body volumes exposed 
to different doses. 
Abbreviations: Tp53+/-, heterozygous for tumor protein 53 gene; F1/2, filial generation 1 and 2; AN, 
anesthesia only control group; CBCT, cone-beam computed tomography controls; VMAT, volumetric-
modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior; CT, computed tomography; Gy, 












































MATERIALS AND METHODS 
19 
Two control groups were formed: one for the treatment with anesthesia only (AN group) and 
another for additional positioning scanning with CBCT (CBCT group). Rats belonging to 
further four radiation treatment groups were aimed to receive, additionally to anesthesia and 
CBCT, either 15 Gy or 24 Gy total doses divided into three equal fractions and delivered every 
other day with VMAT or AP/PA irradiation techniques: 3×5 Gy VMAT, 3×5 Gy AP/PA, 3×8 
Gy VMAT, 3×8 Gy AP/PA. Each group consisted of n = 15 rats. 
Animals were followed up until they showed tumor-associated symptoms and a tumor was 
detectable. Rats were euthanized for the further standardized autopsy to prepare tumors and 
normal tissue samples for subsequent pathological and molecular characterizations. 
 
2.2.2 Animal housing 
Rats were housed in conventional rat cages, (rat standard 1500 cm2 cage, Tecniplast, 
Hohenpeissenberg, Germany) in the animal facility of the medical research center of the 
medical faculty Mannheim of Heidelberg University, under controlled conditions (12-hour 
light/dark cycle, room temperature 22 ± 2°C, 45% ± 5% relative humidity). 
Animals were supplied by a grain-based regular diet (SSNIFF Spezialdiäten) and water (ad 
libitum). 
The results of the quarterly hygienic screenings were always negative for any new pathogens 
for the entire breeding and living period of animals. This was made to excludes possible 
influences of infections on the standardization of the experimental model and thus on the 
experimental results. 
 
2.2.3 Animal breeding 
The accurately performed genotyping-guided breeding method, daily monitoring, and 
controlled environmental conditions provide an optimal basis for lifespan experiments with 
p53-insufficient rats. 
Local breeding was carried out to produce experimental Tp53+/C273X rats. Breeding animals 
were placed into the individually ventilated cages (Rat 1500 cm2 IVC cage) under controlled 
conditions: temperature 22 ± 2°C, humidity 45% ± 5%, ventilation 10 – 15 air changes per hour, 
and a lighting cycle of 12 hours light/dark. The offspring (aged 4 weeks) were separated from 
the mother before the weaned animals received their identities (Table A1). From this time on 
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rats were housed in sex-separated groups of maximal four animals per standard 1500 cm2 rat 
cage.  
Due to an expected accumulation of spontaneous mutations in Tp53 knockout rats, the mating 
age was kept as low as possible: median 110 days for females (XX) and 89 days for males (XY), 
with a 75% confidence interval of [86 – 160] and [76.8 – 160] for XX and XY respectively. 
Heterozygous n = 37 rats of filial generation 1 (F1) belonging to litters 1 – 3 (L1 – L3) were 
derived from 2 male and 3 female parents with the same heterozygous Tp53+/C273X genotype. 
The F2 rats (n = 53) of L4 – L11 were provided from homozygous (Tp53C273X/C273X) males (n 
= 8) and wild type (Tp53C273/C273) females (n = 7) of F1 generation. Taken together, only five 
ancestral knockout allele variants are drifted among all experimental animals of F1 and F2 
generations (Table M1, Table A1 and Table A2).  






Recruitment of rats to experimental groups. Tp53+/C273X rat litters (L1-L11) of the F1 and F2 
generations were randomized in order to balance the ancestral background. The numbers indicate the 
rats. 
 
Rats per litter 
and group 
F1 F2 Total 
L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 L11 
AN 4 - 5 2 0 0 0 0 4 0 0 15 
CBCT 5 1 4 3 0 0 2 0 0 0 0 15 
VMAT 3×5 Gy  6 - 3 1 0 0 4 0 1 0 0 15 
AP/PA 3×5 Gy  5 1 3 4 0 0 1 0 1 0 0 15 
VMAT 3×8 Gy  0 0 0 0 1 4 0 3 0 4 3 15 
AP/PA 3×8 Gy  0 0 0 0 1 5 0 2 0 2 5 15 
Total 20 2 15 10 2 9 7 5 6 6 8 90 
 
Abbreviations: F1 and F2, filial generation 1 and 2; L1 – L11, litters L1 – L11; AN, anesthesia only 
group; CBCT, cone-beam CT only; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-
posterior/posterior-anterior irradiation; Gy, Gray; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy. 
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The weight of animals at the treatment was well-balanced by the gender-balanced distribution 







Weight and age of female and male rats at treatment. The median values (with minimum to 
maximum intervals) of the weight of female and male rats per group are arranged separately and those 
of the age are combined.  
 
Parameters per 
group and sex 
Weight (gram) Age (days) 
XX XY XX/XY combined 
median [min. – max.] median [min. – max.] median [min. – max.] 
AN 162.5 [150 – 190], n = 6 205.0 [175 – 305], n = 7   82.0 [63 – 108], n = 13 
CBCT 182.5 [155 – 200], n = 8 272.5 [175 – 295], n = 6 69.0 [64 – 96], n = 14 
VMAT 3×5 Gy  180.0 [170 – 185], n = 7 242.5 [225 – 280], n = 8 68.0 [58 – 85], n = 15 
AP/PA 3×5 Gy  185.0 [155 – 225], n = 9 250.0 [225 – 285], n = 5 68.0 [58 – 85], n = 14 
VMAT 3×8 Gy  215.0 [185 – 225], n = 7 287.5 [220 – 335], n = 6 106.0 [81 – 124], n = 13 
AP/PA 3×8 Gy  205.0 [180 – 215], n = 7 285.0 [215 – 330], n = 8 106.0 [81 – 116], n = 15 
 
Abbreviations: XX, female; XY, male; n, number; AN, anesthesia only; CBCT, cone-beam CT only; 
VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior irradiation; Gy, 





The median age (gender-mixed) was 37.5 days higher for the 3×8 Gy irradiated groups 
compared to all other groups (106 [81 – 124] vs. 68.5 [58 – 108] days, respectively). The 
possible impact of the age variability on treatment outcomes is discussed below in section 4.6. 
Taken together, these preparations helped to standardize the experimental model for 
comparison of experimentally obtained data between groups containing subjects with relatively 
similar risk factors. 
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2.2.4 Identification of animals  
For identification of animals an ear marking method was used. The incidental tissue sample 
was used for subsequent genotyping. Therefore, an animal was placed in a polycarbonate 
narcosis box (made by the orthopedics laboratory of the university medical center Mannheim) 
saturated with isoflurane using a small animal vaporizer device. Prior to the ear punching rats 
received short (< 1 minute) inhalation anesthesia (isoflurane, FORENE® 100% V/V). An ear 
punch tool (Fine Science Tools) was used for earmarking making samples with a diameter of 2 








Fig. M2. Earmarking. A combination of punches represents the identity. The arrow directed from the 




Earmarking. A combination of the ear punches represents the identity. The arrow directed from the 





2.2.5 Preparation of animals for CT and RT 
Prior to irradiation and CT scanning, rats underwent continuous narcosis to sleep over the whole 
procedure duration, which was in the range of about 1 hour for a foursome group of animals. 
For this purpose, the initial sedation was made by a short inhalation of FORENE®, as mentioned 
in section 2.2.4. Subsequently, rats received a subcutaneous injection of an anesthesia mixture 
of 0.15 mg medetomidine (Domitor®), 2.0 mg midazolam (Midazolam-ratiopharm® 15 mg/3 
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For transportation of an anesthetized rat, a single use individually ventilated transport cage 
(SUMC, 501 cm2) was used, which is equipped with a microfiber filter hood protecting animals 















Preparation of rats for irradiation and CT. (a) Shown is a foursome group of narcotized male rats 
fixed in disposable cage for transportation. (b) An anesthetized female rat with an inserted tail vein 





Narcotized rats were placed in the cages and secured to the bottom of the cage by tapping the 
extremities and tails using tape (Rollenpflaster). 
To absorb anesthesia-related urinary urgency, 3 – 4 compresses (RS-Mullkompressen 7.5×7.5 
cm) were put underneath the animals. 
An eye ointment (Bepanthen® Augen- und Nasensalbe) was applied to rats to prevent the cornea 
from drying out during the narcosis. 
For rehydration, narcotized animals received subcutaneous depot-injection of 2 ml 0.9% 
isotonic saline solution per 250 g of their body mass using 22G Neoject cannulas and 2 ml or 5 
ml single use syringes (Injekt Disposable Syringes).  
The cages with narcotized and fixed rats were closed with filter hoods remaining over the whole 
transport and radiation procedure period, for the pathogen-safety. 
a b 
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After experimental procedures were finished, to antagonize the residual anesthetics, sleeping 
rats received a subcutaneous injection of 0.3 mg naloxon (Naloxon Actavis® 0.4 mg/ml), 0.5 
mg flumazenil (Anexate® 0.5 mg/5ml), and 2.5 mg atipamezole (Antisedan® 5 mg/ml). 
Shortly prior to CT examination, a contrast agent was injected intravenously using a self-
constructed catheter system consisting of a 26 g CLiP® neo safety intravenous catheter (Vygon 
- Vigmed), which was connected to a flexible polyethylene tube (PORTEX® PE with 0.58/0.96 
mm inner/outer diameter) with luer-lock connectors, and was terminated by a closing cone 
(Combi stopper PE closing cone). The catheter was inserted into a tail vein of an animal (Figure 
M2b). The catheter was charged with isotonic saline solution to avoid the impermeability of 
the tubes during the transportation. The contrast media applied via the catheter using tuberculin 
syringes. 
 
2.2.6 Radiation planning and dose delivery 
Two template CTs for radiation planning were taken from 250 g male (large) and 170 g female 
(small) rats using a routine clinical planning CT device (Philips Brilliance Big Bore,120 kV). 
For the contouring of the body structures for irradiation planning a Monaco® (version 5.0) 
treatment planning system from ELEKTA was used. 
The whole-body (‘patient’) volume of the rat and organ-structures at radiation risk were 
contoured separately on each of two planning CTs (small and large): head, brain, heart, 
diaphragm, thymus, sternum, neck, spine, liver, stomach, colon and bladder as well as the right 
and left lungs, chest walls, axilla, forelimbs, dorsal muscles and kidneys. Representative dose 
to volume relationships (DVR) for these structures at risk of 3×5 Gy delivered with small or 
large VMAT and AP/PA plans are given in Table A4. 
A cylindrical 296 mm3 PTV with an approximated radius of 0.5 mm and a high of 10 mm within 
the mediastinum of the rat, was similarly defined on both planning CTs. 
Based on these two planning CT datasets, the plans for the dose delivering techniques (360° arc 
VMAT and two opposing AP/PA beams) were constructed separately for each body masses 
(plan size). 
Recruitment of n = 30 female and n = 27 male rats to each treatment plan size (small, ≤ 215 g 
or large, ≥ 220 g), the total doses (3×5 Gy or 3×8 Gy), and irradiation techniques (VMAT or 
AP/PA) is given in Table M3. 
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Table M3 
Recruitment of female and male rats to particular radiation plan size. Given are applied irradiation 
plans (large or small), dose delivering technique (VMAT or AP/PA), and prescribed doses (3×5 Gy or 
3×8 Gy). The numbers indicate rats without dropout animals. 
 
Plan size for XX and XY 
rats per treatment group 
XX XY 
large plan  small plan  large plan  
VMAT 3×5 Gy  0 7 8 
AP/PA 3×5 Gy  1 8 5 
VMAT 3×8 Gy  3 4 6 
AP/PA 3×8 Gy  0 7 8 
Total 4 26 27 
 
Abbreviations: XX, female; XY, male; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-





The fraction dose to the PTV was defined as 5 Gy for 3×5 Gy and 8 Gy for 3×8 Gy irradiation. 
The beam on time of the delivery of 5 Gy to the PTV was approximately 45 seconds for full arc 
VMAT and 30 seconds for AP/PA. These were expanded to 60 seconds and 45 seconds for the 
delivery of 8 Gy respectively VMAT and AP/PA. Thus, the estimated dose rate (Gy/minute) 
for VMAT was higher than for AP/PA. The dose rates were not affected by the different 
treatment plan sizes (small or large). 
Representative images of contoured organs (structures) at radiation risk and the PTV, as well 
as DVRs and dose-volume histograms (DVHs) in a rat thorax irradiated with VMAT or AP/PA 
beams, shown in Figure M4. 
For the irradiation accuracy, an image-guided irradiation method performed using CBCT. For 
this procedure, rats in transport cages were initially positioned using laser beams (Figure M5a).  
CBCT was taken from each rat before each treatment fraction to match it with prescribed 
treatment plans and to correct the position of the PTV as precisely as possible using positioning 
software MOSAIQ® (Figure M5b – c). The deviations in each of the three-dimensional 
directions between treatment plans and CBCT were scarcely different between animals, as 
exemplarily shown in Figure M5c. 





































Radiation planning for VMAT and AP/PA. (a) Contouring of the ‘structures’ at radiation risk (color 
panel) and the PTV (red) in the mediastinum of the rat (coronal view). (b) Radiation dose distribution 
for VMAT and AP/PA techniques (colored area). (c) The DVHs for the PTV, and integral dose 
(‘patient’) for VMAT or AP/PA irradiation (permanent and dashed, respectively). (d) DVHs for selected 
thoracic organs at risk and the PTV for VMAT and AP/PA. (e – f) Total DVHs of 5 Gy fraction delivered 
with (e) VMAT or (f) AP/PA. Screenshots are from the small treatment plans. 
Abbreviations: PTV, planning target volume; VMAT, volumetric-modulated arc therapy; AP/PA, 
anterior-posterior/ posterior-anterior; Gy, Gray; DVRs, dose to volume relationships; DVHs, dose to 
























Positioning for image-guided irradiation. (a) An anesthetized rat located under the gantry of the 
LINAC using positioning laser beams (green); (b – c) CBCT matching with the planning CT scan 
(magenta/green) and correction of the couch position for irradiation accuracy. 






2.2.7 Observation phase 
During the entire follow-up period (median 254 [91 – 431] days), rats were monitored daily to 
detect typical signs of a sickness such as rough hair coat, porphyrin staining, apathy, abnormal 
breathing, orbital tightening, limb paralysis, or a visible tumor mass. 
From the age of four weeks all rats underwent weekly weight controls to collect individual 
growth data and to define a progressive weight loss of more than 10% – 20% of the attained 
body weight. Obtained growth data was documented, ordered by various parameters, and 
assembled in Table A1C – F. 
 
2.2.8 Tumor detection using high-resolution low-dose CT 
In addition to regular health checks, animals were examined with a high-resolution ultra-low 
dose (spatial resolution 0.24 mm, < 50% compared to conventional systems) CT scanner 
SOMATOM Force®. This dual-source CT system was aimed to deliver high-quality images 
even at very fast respiratory and cardiac activities in rats (60 – 170 breaths per minute and 300 
a b c 
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– 500 heartbeats per minute, respectively). It has also been supposed that these parameters could 
decrease substantially due to narcosis. 
An iodinated contrast agent (Imeron®-300) was applied by intravenous administration via a 
catheter inserted in a tail vein (2 – 4 µl per gram body mass). The contrast media was not used 
in some cases, in which the scans could not be assisted by the contrast agent due to technical 
errors (the catheter was impermeable or it was lost from a vein). 
During the entire follow up period most rats (n = 77) were examined by SOMATOM Force CT. 
Out of remaining n = 57 rats, n = 45 were examined repeatedly (final CT) as most of that 
appeared to be ill. A list of SOMATOM Force data is compiled in Table A6. The analysis of 
the CT-reconstructions (total body and thorax windows), for an improved image display, was 
performed using versatile imaging software (Syngo.via,). RadiAnt DICOM Viewer was also 
used to visualize the DICOM (digital imaging and communications in medicine) data. 
Representative images are shown below, in Figure M6a. 
For technical reasons, it was not possible to perform final Force CT scans of six rats with 
tumors. However, one of these rats, which had a mediastinal tumor, and another - an axillary 
tumor - were scanned with a micro-CT modified for preclinical applications (Y. FOX) 114,115. 
But these micro-CT scans resulted in images of unsatisfactory quality. Out of the remaining 
four animals, two rats had mediastinal solid tumors located exactly within the HDV, one had a 
bone tumor on the sacral vertebra, and an additional small tumor on a rib. The last one was 
affected by a solid tumor sitting on the right scapula. Thus, these last four malignancies were 
identified during the necropsy and assigned to corresponding predefined volumes. 
 
2.2.9 Euthanasia 
All rats were euthanized using CO2 overdoses. Therefore, animals were placed in a standard rat 
cage with a flat Plexiglas® top connected to the CO2 source with a flexible tubule. The gas was 
delivered during 10 – 15 minutes, with very low pressure with a barely audible flow, until the 
signs of death were identified (cardiac and respiratory arrest). 
 
2.2.10 Assessment of detected tumors to different dose-volumes 
For the assessment of tumors to initially received radiation dose, tumor positions on the final 
CTs were compared with radiation plans using RadiAnt DICOM Viewer and the volumes of 
tumors were visually assigned to the corresponding isodose levels of the radiation plan used. 
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The assignment of tumors to related dose-volume by adjusting the Monaco® treatment plans 























Allocation of tumor positions to different dose volumes. (a) Representative VMAT plan and final 
SOMATOM force CT images of the rat developing rib bone sarcoma within the LDV (upper left and 
right, respectively) and AP/PA plan and final CT with mediastinal lymphoma in the HDV (lower left 
and right). Both are native CTs without contrast media injection. Arrows show the positions of tumors. 
(b) A scale (Monaco®) of the dose distribution in the irradiated volume and assignment of the isodoses 
to the predefined HDV (90 – 107% of the prescribed dose), BHDV (50 – 90%), LDV (5 – 50%), and 
NIRV (< 5%) volumes. 
Abbreviations: VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior; 
CT, computed tomography; PTV, planning target volume; HDV, high-dose volume; BHDV, bordering 
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Based on estimated dose-volume relationships for tumor-affected volumes, isodoses were 
assigned to three predefined dose-volume levels at risk of radiation-induced tumor 
development: high-dose volume (HDV) exposed to at least 90% of the total target doses (3×5 
Gy or 3×8 Gy), bordering high-dose volume (BHDV) receiving 50% – 90%, and low-dose 
volume (LDV) receiving 5% – 50% of total doses (Figure M6b). 
Tumors outside these dose-volumes were assigned to the non-irradiated volume (NIRV) at risk 
of < 5% of the doses.  
Based on Monaco® statistics, the HDV, BHDV, and LDV comprised approximately 0.8 cm3, 
3.9 cm3, and 22.2 cm
3 for the large VMAT-plan while for the large AP/PA-plan 2.5 cm3, 4.3 
cm3 and 12.0 cm3 were measured respectively. For smaller animals (plan size small), the 
volumes to the HDV, BHDV, and LDV were about 0.7 cm3, 2.9 cm3, and 12.4 cm3 for VMAT 
and 1.3 cm3, 3.4 cm3, and 7.4 cm3 for AP/PA. 
The DVRs of tumors, corresponding to different body volumes receiving different doses or no 
doses before tumors arose, are given in Table A3E – H and Table A4. 
 
2.2.11 Necropsy 
Sacrificed rats were fixated on a dissection cork plate (30×30 cm Rotilabo®-Presskork-
Untersetzer), covered with a pulp-made pad (20×40 cm MaiMed Absorbent Pads), and 
moistened with 70% ethanol. 
First the skin was incised across the inguinal-pelvic area and cut up to the mandible, prior to 
open abdominal and thoracic cavities using strabismus scissors and tissue forceps. The thorax 
and the abdomen were then opened for visual inspection by making a longitudinal incision 
along the length axis. 
All visible organs in the abdominal and thoracic cavities, head, neck, and extremities were 
visually examined for abnormalities such as swelling, changes in the consistency of the tissue 
surfaces, fluid accumulation, differences in size and displacements of the organs, and, 
especially for additional tissue. 






























Gross necropsy and tissue sampling. (a) Representative autopsy of a female rat: (1) trachea, (2) 
thymus, (3) heart, (4) aortic arch, (5) lungs, (6) ribs, (7) lymph node, (8) mamma, (9) diaphragm, (10) 
liver, (11) right kidney, (12) stomach, (13) spleen, (14) pancreas, (15) colon, (16) cecum, (17) right 
ovary, (18) oviduct, (19) uterus, and (20) bladder. (b) Schematic workflow of tissue analyses.  
Abbreviations: FFPE, formalin-fixed paraffin-embedded; H&E, hematoxylin and eosin; gDNA, 





2.2.12 Collecting tissue samples 
For the preparation of the tissue samples, entire thoracic and abdominal organs including lungs, 
heart, thymus, trachea, esophagus, lymphatic tissues, large thoracic blood vessels, diaphragm, 
chest wall with ribs, thoracic vertebrae, liver, spleen, pancreas, bladder, and other evidently 
altered organs/tissues as well as tumors were removed separately using surgical disposable 
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Tissue samples were preserved in 3.7% buffered formalin into the 100 ml sample beakers for 
at least 48 hours. The formalin solution consisted of 800 ml distilled water, 100 ml 10× 
phosphate-buffered saline (PBS; 80 g NaCl, 2 g KCl, 2.4 g KH2PO4 ∙ 2H2O; set on pH 7.4), and 
100 ml 37% formaldehyde solution (ROTIPURAN® 37% formaldehyde solution. 
Small fragments of the tumors for DNA-extraction from n = 40 rats were shock-frozen in liquid 
nitrogen and stored at - 80 °C in a freezer (Panasonic MDF-DU700VH Freezer). 
The representative workflow of removing and preparations the tissues for subsequent 
pathological and molecular examinations is expressed above in Figure M7b. 
 
2.2.13 Histopathology 
Organ samples from irradiated and unirradiated rats were prepared similarly. 
These organs collected during the necropsy and saved in formalin were sectioned in about 0.5 
cm thick slices under the cell bench (HERAsafe® KSP12) using scalpel (Surgical Disposable 
Scalpels), forceps (a standard pattern forceps, and a tissue forceps), and scissors (Fine scissor - 
sharp/blunt) 
Chest organs such as the lungs (at least 4 samples), trachea (1), solid blood vessels (2 - 4), 
esophagus (1) with surrounding fat and mesothelium were cut axially at the PTV level. 
Liver tissue samples (1-2) were taken from the apical parts of the medial lobe. Further tissue 
sections of diaphragm (at least 1), stomach (1 – 2), spleen (1) pancreas (1), colon (2 – 3), bladder 
(2 – 3), reproductive organs (2 – 3), brain (2 – 4), as well as left and right chest wall sections (2 
– 4) with the nearest mamma fragments were cut always along the axial plane. 
Soft tissue tumors were cut across the middle of the mass to visualize its center and periphery 
(at least 2 sections). Large tumors thereof were further sliced successively in approximately 0.5 
cm thick sections (2 – 4). The neoplastic bone tissue structures were sectioned similarly to soft 
tissue tumors and soaked in a solution containing ethylenediaminetetraacetic acid (Decalcifier 
Soft), for at least 3 days. 
The formalin-fixed tissue pieces were placed into the tissue cassettes (neoLab embedding 
cassettes) for dehydrogenizing by about 55 °C overnight in a drying cupboard (Heraeus®), 
before preparing formalin-fixed paraffin-embedded (FFPE) tissue blocks, which were poured 
on a paraffin-casting machine (Leica HistoCore Arcadia). 
FFPE tissue blocks were cooled on a cooling plate unit (Leica EG 1150 C) before slicing in 4 
– 6 µm sections with a microtome (Leica RM2245) using C35 carbon steel blades, common 
fine brushes and a Dumont #5 forceps. 
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To remove paraffin before the staining, FFPE tissue sections were placed on 76×26×1 mm 
microscope object-slides using 38 °C warm water bath (LEICA HI1210) and then incubated at 
about 55 °C overnight into the Heraeus® drying cupboard. 
Histopathological staining of the tissue slides with hematoxylin and eosin (H&E) was carried 
out on an automatized tissue staining station (Leica Autostainer XL). The H&E-stained tissue 
samples on the object slides were embedded in a mounting medium (Roti®-Histokit), covered 
gently with covering glasses (Microscope Cover Glasses 15H 24×50 mm) using a forceps 
(Cover Glass Forceps 4×0.6×105 mm), and saved to dry overnight at room temperature in an 
air-flow safety bench (Prutscher S/TA/120/1297). 
Morphological evaluation of samples was done using an upright microscope equipped with a 
digital microscope camera (LEICA DMBRE with Leica DFC 450). This final evaluation of 
H&E-stained tissue slides was performed in the Medical Research Center and the Institute of 
Pathology of the University Medical Center Mannheim by experienced pathologists. 
 
2.2.14 Extraction of genomic DNA 
For the extraction of genomic DNA (gDNA), the frozen tumor samples were fixed on a cryostat 
(Leica CM3050-S cryostat) using an adhesive compound (Tissue-Tek® O.C.T.™) to cut that in 
6 µm thick layers using stainless steel R35 blades. The gDNAs were similarly extracted from 
ear punches and frozen tumor samples using an extraction kit (KAPA Express Extract Kit). The 






Extraction of the gDNA. Components per 2 – 3 ear-punches or 3 – 5 tumor slices (6 µm). 
 
Components Ear tissue samples Frozen tumor samples  
10 × KAPA Express Extract Buffer  5 µl 10 µl 
KAPA Express Extract Enzyme (1U/µl) 1 µl 2 µl 
PCR grade H2O 44 µl 88 µl 
 
Abbreviations: gDNA, genomic DNA; PCR, polymerase chain reaction. 
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The extraction was performed by an initial lysis step (15 – 20 minutes at 75 °C) and followed 
by enzyme inactivation (5 minutes at 95 °C). 
The extraction was carried out in standard 1.5 ml tubes (Eppendorf, Hamburg, Germany), and 
the thermo-chemical part of the procedure made using a thermo-mixer (Eppendorf® 
Thermomixer Compact). For long-term storage, gDNA extracts were saved at - 20 °C. 
 
2.2.15 DNA amplification using PCR 
Amplification of core fragments of endogenous Tp53 gene from each 1 µl crude extracts, 
containing about 10 – 30 ng template gDNA per reaction, was performed using KAPA2G Fast 
PCR Kit. The PCR primer positions at the rat Tp53, flanking the thymine to adenine substitution 













PCR primer-positions at the rat Tp53 DNA. Schematic representation of Chr10 fragment of Rattus 
norvegicus containing the Tp53 gene with a T/A 56196114 alteration of the mutational hotspot codon 
C273 in 6th exon. Boxes and lines represent exons and introns, respectively. Arrows indicate the 
approximate positions of the PCR primers used in the experiment. 
Abbreviations: Tp53, Tumor protein 53; for, forward; rev, reverse; T, thymine; A, adenine; Chr10, 
chromosome 10.  
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As a positive gDNA control, the 240 bp spanning fragments of the rat housekeeping gene 
Glyceraldehyde-3-phosphate-dehydrogenase (Gapdh) were amplified from the gDNA extracts 
of ear-punches and tumor samples using a self-designed specific primer-pair Gapdh-for and 
Gapdh-rev. 
The purity of the reactions was tested by negative control PCRs containing H2O instead of 
template DNA. 
The expected sizes of the PCR products corresponding to used Tp53 primer pairs were compiled 






PCR primer pairs and expected sizes of corresponding amplicons.  
 
 





The forward primers Rat-Tp53-for1, Rat-Tp53-for2, or Rat-Tp53-for3 were combined with 
reverse primers Rat-Tp53-rev1, Rat-Tp53-rev3, or Rat-Tp53-rev4 to amplify 772 – 879 base 
pairs (bp) long fragments of the Tp53 gene containing C273 coding site (Table M5 and Table 
M6a – a´).  
Forward primer Reverse primer Product size 
Rat-Tp53-for1 Rat-Tp53-rev3 879 bp 
Rat-Tp53-for1 Rat-Tp53-rev4 729 bp 
Rat-Tp53-for2 Rat-Tp53-rev3 834 bp 
Rat-Tp53-for3 Rat-Tp53-rev2 772 bp 
Rat-Chr10-for Rat-Chr10-rev 4523 bp 
Rat-Tp53-for1 Rat-Chr10-rev 2650 bp 
Rat-Chr10-for Rat-Tp53-rev3 2752 bp 
Gapdh-for Gapdh-rev 270 bp 
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Table M6 
PCR amplification of the rat Tp53 gDNA: (a) rat and tumor genotyping Tp53 PCR, (b) PCRs for 
tumor genotyping and Tp53 LOH analyses, (c) nested Tp53 PCR products. (a´ – c´) The cycler programs 
for the reactions given in a – c.  
 
 
PCR for 772 – 879 bp products  50 µl/sample 
KAPA2G PCR mix 25 µl 
Rat-Tp53-for1, Rat-Tp53-for2 or Rat-Tp53-for3 5 – 10 pmol/µl 
Rat-Tp53-rev2, Rat-Tp53-rev3 or Rat-Tp53-rev4 5 – 10 pmol/µl 
Template (gDNA) 0.5 – 1.5 µl 




PCR for 4523 bp products 50 µl/sample 
GoTag®Long PCR Master Mix 25 µl 
Rat-Chr-10for 5 – 10 pmol/µl 
Rat-Chr10rev 5 – 10 pmol/µl 
Template (gDNA) 1 – 1.5 µl 




Nested PCR for 2650 bp and 2752 bp products 50 µl/sample 
GoTag® colorless PCR Master Mix 25 µl 
Rat-Chr10-for or Rat-Tp53-for1 5 – 10 pmol/µl 
Rat-Tp53-rev3 or Rat-Chr10-rev 5 – 10 pmol/µl 
Template (4523 bp PCR product) 0,5 – 1 µl 
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Reaction steps PCR for 772 – 879 bp products 
Temperature Time  
Hot-start* 50 °C 3 – 5 minutes 
Initial denaturing 95 °C 2 minutes 
Denaturing** 95 °C 20 – 45 seconds 
Annealing** 57 – 62 °C 20 – 45 seconds 
Elongation** 72 °C 1 – 1.5 minutes   
Final elongation 72 °C 3 – 5 minutes 
* If required; ** steps were repeated in 34 – 36 cycles. 
 
 
Reaction steps PCR for 4523 bp amplicons 
Temperature Time  
Initial denaturing 94 °C 3 minutes   
Denaturing* 95 °C 30 – 45 seconds 
Annealing* 60 °C 15 – 20 seconds 
Elongation* 60 – 72 °C 5 minutes 
Final elongation 72 °C 12 minutes 
* 32 or 34 cycles. 
 
 
Reaction steps Nested PCR products 
Temperature Time  
Initial denaturing 94 °C 3 minutes   
Denaturing* 95 °C 15 seconds 
Annealing* 60 °C 15 seconds 
Elongation* 72 °C 3 minutes 
Final elongation 72 °C 9 minutes 
* 34 or 36 cycles. 
Abbreviations: Tp53, Tumor protein 53; gDNA, genomic DNA; PCR, polymerase chain reaction; for, 




MATERIALS AND METHODS 
38 
The 4523 bp long PCR copies of Tp53 were amplified with Rat-Ch10-for and Rat-Ch10-rev 
primer pair from approximately 0.5 – 1 µl tumor gDNA extracts using a long PCR kit 
(GoTag®Long PCR Master Mix), and an adapted protocol to optimize the yield of PCR products 
as given in Table M6b – b´. 
The 4523 bp spanning PCR products were used as templates for the nested amplification of 
2650 bp (Tp53-for1/Chr10-rev) or 2752 bp (Chr10-for/Tp53-rev3) DNA fragments (Table 
M6c – c´). These long sequence amplifications were performed to check the integrity of the 
C273 coding site within the Tp53 gene locus. 
For some PCRs producing DNA copies being not enough for purification and sequencing or 
could be poorly detected in agarose gels, a further nested PCR approach performed using primer 
pairs either Tp53-for1/Tp53-rev3 or Tp53-f2/Tp53-rev3 and GoTag® colorless PCR Master 
Mix. 
 
2.2.16 Agarose gel electrophoresis 
Agarose gels were prepared in 50 ml or 100 ml 1× TAE (121.14 g/mol TRIS [tromethamine ≥ 
99.9%], 60.05 g/mol acetic acid [≥ 95.9%], and 292.25 g/mol EDTA [≥ 99%]) buffer with 1% 
– 1.2% agarose (Roti®garose Low Melt). Gels were stained with 6 µl DNA dye (Gel Red) per 
100 ml gel volume. 
For quality control of the PCR products, each 2 µl reaction was mixed with 2 µl loading buffer 
(Purple Loading Dye 6×) and filled with water, up to 12 µl total volume, to load on an agarose 
gel. 
The electrophoretic separation of the PCR product DNA was done under electrical power, with 
a potential of 80 – 100 millivolt and a charge of 70 – 116 milliampere, for 0.5 – 1.5 hours using 
the standard gel-electrophoresis chamber. The chamber was filled with 1× TAE buffer and 
connected with a source (OwlTM EC-105 Compact Power Supply). 
As molecular mass standard, a 0.1 – 10 kb (kilo-bases, 103 bases) DNA ladder (2-Log DNA 
Ladder, New England BioLabs, Frankfurt, Germany) was used. 
The template-free negative controls for each PCR were also loaded on the gels to secure the 
purity of the PCR master mixes. 
The PCR products stained in agarose gel during electrophoresis visualized using an ultra-violet 
transilluminator imager (INTAS Gel iX20). The data was documented with gel documentation 
device INTAS capture software. Representative gel images are shown below in results section 
3.7. 
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2.2.17 DNA purification 
PCR products purified either using column chromatography (mi-PCR50 Purification Kit) or 
enzymatically using a cleanup kit containing Exonuclease I and a shrimp alkaline phosphatase 
rSAP (Rapid PCR Cleanup Enzyme Set). 
The column chromatography carried out according to the manufacturer’s manual with variable 
elution volumes: 25 µl, 50 µl, and 100 µl. 
For the enzymatic purification, each 1 µl Exonuclease I and 1 µl rSAP were added to 5 µl PCR 
product and incubated at 37 °C for 5 minutes prior to thermal inactivation of enzymes at 80 °C 
for 10 minutes in a thermal block (Eppendorf® Thermomixer Compact). 
The concentration of purified PCR-products was ensured by photometry (Eppendorf Bio 
Photometer). For these measurements, 2 µl of each purified PCR products were mixed with 98 
µl water and measured by specific extinction at λ = 260 nm in comparison to a blank sample 
(100 µl H2O). 
 
2.2.18 DNA sequence analysis 
The PCR products were sequenced for genotyping of animals as well as analyzing of LOH in 
tumors. 
For Sanger sequencing, about 10 – 100 ng/µl of purified PCR products were mixed with 5 µM 
either forward primers (Tp53-for1, Tp53-for2, Tp53-for3) or reverse primer Tp53-rev4 and 
filled with nuclease-free water up to 10 µl total volume in 1.5 ml Eppendorf tubes. Samples 
were incubated for 5 minutes at 95 °C to eliminate possible protein contaminations before 
labeling with Sample barcodes (LightRun Tube® Barcodes), and sent to Eurofins GATC 
Biotech to accomplish the sequencing reaction and data supply. 
A plasmid Editor (ApE, v2.0.49) was used for the design of PCR-primers (which were 
synthesized by Metabion international AG, Germany) and for the analysis of the sequences 
based on Rattus norvegicus data version 6.0 (Rnor_6.0; INSDC Assembly GCA_000001895.4, 
July 2014). 
The heterozygosity (Tp53+/C273X) of experimental rats was ensured by recognizing the transition 
of C273 coding TGT to TGA (stop codon) in one of two Tp53 alleles localized on chromosome 
10 of the rat. Heterozygous Tp53+/C273X genotype, in which the C273-encoding triplet appears 
mutated in only one allele, was recognized by relatively similar levels of T/A nucleotide peaks 
MATERIALS AND METHODS 
40 
on the sequencing chromatograms. In contrast, LOH (Tp53C273X/C273X) in tumors identified by 
an A/T ratio of ≥ 2.0. 
Examples of sequencing chromatograms are shown below in results 3.7. 
 
2.2.19 Inflammation analysis 
Investigation of visible structural changes occurred evenly in cross-sections of irradiated and 
unirradiated chest organs, proposed to provide new information on the relationships between 
radiation-induced inflammation and SC development. 
Inflammation in irradiated thoracic tissues from n = 19 rats developing tumors in the NIRV and 
n = 22 controls (AN/CBCT, combined) were analyzed microscopically (1 – 4 slides per rat) by 
a pathology professional at the institute for pathology at the university medical center 
Mannheim. 
Agglomerations of lymphocytes, which were almost exclusively detected in the lungs during 
microscopy. These lymphocytes foci, assumed to be indicators of inflammation, were graded 
as 0 (none), 1 (rare), 2 (moderate), or 3 (frequent), according to their frequency.  
The events detected by pathological inflammation analysis were compared between irradiated 
and non-irradiated animals and in animals treated with VMAT vs. AP/PA. 
 
2.2.20 Storage and availability of data and samples 
All experimental data are documented in laboratory books 1 and 2 which also refers to the data 
saved on WD Server (#WCC4E2NJO3Y6, WD®) comprising all the microscopy images, 
photos, as well as SOMATOM force CT data generated and saved on the server 
(‘RADWIPACS’) of the department of clinical radiology and nuclear medicine of the university 
medical center Mannheim. 
All collected materials such as frozen tissue fragments, FFPE tissue blocks, and derived H&E-
stained tissue slides, gDNA extracts, and PCR-Products are saved at the cellular and molecular 
radiation oncology laboratory of the department of radiation oncology of the university medical 
center Mannheim. 
 
MATERIALS AND METHODS 
41 
2.2.21 Statistical analyses 
The frequency of tumor development in differently exposed volumes (HDV, BHDV, LDV) and 
non-exposed volume (NIRV), as well as the appearance of LOH in tumors and inflammation in 
tumor-free lungs, were compared using Fisher’s exact test or Chi-square test (retrospective 
contingency analyses). 
The lifespan between radiation treated and control groups was compared using Kaplan-Meier 
survival curves and the Gehan-Breslow-Wilcoxon test. 
The latency TTT, from treatment time point to appearance of tumors, was tested using the 
Mann-Whitney test. 
The comparisons were made with respect to treatment techniques (VMAT or AP/PA), radiation 
doses (3×5 Gy or 3×8 Gy), isodose levels (LDV, BHDV, and HDV), used treatment plan size 
(small or large), weight categories, sex, and the age at the treatment of animals. 
The limit of significance for all statistical tests was defined as α < 0.05. 
GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA) was used for data visualization 




3.1 Tumor incidence in different dose volumes 
The occurrence of tumors was expected in both irradiated and non-irradiated body volumes of 
cancer-prone rats. The aim was to compare the rates of radiation-associated tumors between 
differently exposed volumes (LDV, BHDV, and HDV) with the rates of sporadic tumors in 
non-exposed volumes (NIRV). 
At least one tumor (index tumor) was detected in n = 84 animals, while n = 6 animals were lost 
due to other causes and, therefore excluded from the analysis (Table A1 and Table A3). 
The data collected from n = 84 rats were used to analyze tumor development after VMAT vs. 






Tumor incidence in unirradiated and irradiated body volumes. Numbers represent rats with index 
tumors. The total sums indicate the number of animals with index tumors within the same dose volume 
and the assignment of these animals to the treatment groups.  
 
Incidence per group NIRV LDV BHDV HDV Total 
AN 13 0 0 0 13 
CBCT 14 0 0 0 14 
VMAT 3 × 5 Gy  5 2 1 7 15 
AP/PA 3 × 5 Gy  7 1 1 5 14 
VMAT 3 × 8 Gy  9 0 0 4 13 
AP/PA 3 × 8 Gy  3 4 1 7 15 
Total 51 7 3 23 84 
 
Abbreviations: NIRV, non-irradiated volume; LDV, low-dose volume; BHDV, bordering high-dose 
volume; HDV, high-dose volume; AN, anesthesia only controls; CBCT, cone-beam computed 
tomography only controls; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-
posterior/posterior-anterior irradiation; Gy, Gray; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy. 
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The analysis showed that, in both control groups (AN/CBCT), all n = 27 tumors were found in 
the sham NIRV of rats, similar to n = 24 of n = 57 animals from four irradiated groups with 
tumors in the corresponding NIRV.  In contrast to this (p < 0.0001), tumors in n = 33 irradiated 






















Development of sporadic and radiation-induced tumors. (a) All tumors in combined AN/CBCT 
controls were found within sham NIRV, similar to irradiated animals that developed tumors in NIRV 
and unlike rats with tumors found in the irradiated volume (LDV/BHDV/HDV) (Chi-square test). (b) 
Tumor rates between NIRV and LDV/BHDV/HDV were not significantly different after 3×5 Gy and 
3×8 Gy (Fisher’s exact test). (c) Proportions of tumors in either dose volumes were similar after 3×5 Gy 
vs. 3×8 Gy (Chi-square test). (d) Tumors in NIRV and LDV/BHDV/HDV similarly occurred in rats 
treated with VMAT and AP/PA (Fisher’s exact test).  
Abbreviations: AN, anesthesia only; CBCT, cone-beam computed tomography only; NIRV, non-
irradiated volume; LDV, low-dose volume; BHDV, bordering high-dose volume; HDV, high-dose 
volume; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior 
irradiation; Gy, Gray; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy. Connecting with a slash means 
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The incidence of radiation-associated tumors in the LDV/BHDV/HDV and in NIRV did not 
differ significantly (p = 0.1) between rats treated with 3×5 Gy (n = 17 and n = 12) compared to 
3×8 Gy (n = 16 and n = 12) (Figure R1b). 
Importantly, the majority (n = 23) of n = 33 radiation-associated tumors were detected inside 
the volume receiving highest doses (HDV), only n = 3 in the BHDV, and n = 7 in the LDV (3×5 
Gy/3×8 Gy combined). Thus, the total number of rats with a tumor within the HDV was more 
than doubled compared to the number of rats (n = 10) developing tumors in volumes exposed 
to relatively lower doses (BHDV/LDV, combined). 
In rats treated with 3×5 Gy, compared to 3×8 Gy, no significant difference could be observed 
between the incidence frequencies within LDV, BHDV, HDV, and NIRV (Figure R1c). 
Most notably, no increased tumor induction was observed in the volume irradiated with VMAT 
compared to AP/PA (14 of 28 vs. 19 of 29, p = 0.44) (Figure R1d). Thus, the RR of tumor 
development after VMAT (IMRT) was not increased compared to AP/PA (3D-CRT) treatment 
(RR = 0.79 with a 95% confidence interval of 0.46 – 1.34). 
Taken together, no increased risk of radiation-induced tumors observed in the volumes exposed 
to lower doses compared to higher doses or in rats treated with VMAT compared to AP/PA. 
 
3.2 Frequency distribution of tumors in different dose-volumes 
To illustrate the frequency distribution of tumors developed in different dose-volumes (LDV, 
BHDV, or HDV) and NIRV, a ‘part of whole’ analysis performed. The test aimed to indicate 
the contingency or eventuality of tumor development in differently exposed and unexposed 
volumes. The sizes of unirradiated and uniformly irradiated volumes (Table A3F) summed, 
therefore, to determine the overall size (total volume in cm3) of all tumor-affected NIRVs, 
LDVs, BHDVs, and HDVs (Table A4). 
The frequency distribution of neoplastic events was calculated and displayed for each summed 
volume (NIRV, LDV, BHDV, and HDV), as the ratio of the events per unit volume (cm3), in 
relation to the prescribed total doses (3×5 Gy and 3×8 Gy), treatment modalities (VMAT and 













































1 1  (3 9 .3 % ) H D V  (0 .4 2 % )
1  (3 .5 7 % ) B H D V  (0 .1 6 % )
2  (7 .1 % ) L D V  (1 .0 2 % )
1 4  (5 0 .0 % ) N IR V (9 8 .4 % )
V M A T
1 2  (4 2 .4 % ) H D V  (0 .8 7 % )
2  (6 .9 % ) B H D V  (0 .5 2 % )
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Frequency distribution of cancerous events in different dose-volumes. (a – d) Shown are the part of 
the whole diagrams of tumor-affected volumes receiving different doses. The numbers of index tumors 
reflect the numbers of the incident events within the NIRVs, LDVs, BHDVs, and HDVs receiving < 
0.75 Gy, 0.75 – 7.5 Gy, 7.5 – 13.5 Gy, and 13.5 – 15 Gy during 3×5 Gy irradiation or < 1.12 Gy, 1.12 
– 12 Gy, 12 – 21.6 Gy, and 21.6 – 24 Gy of the total of 3×8 Gy respectively. The percentages represent 
the portions of the total amounts of uniformly exposed volumes and portions of the total events grouped 
by (a) 3×5 Gy and (b) 3×8 Gy or (c) VMAT, and (d) AP/PA treatments. (c) The frequency distributions 
of tumors per NIRVs, LDVs, BHDVs, and HDVs was increased with increased estimated doses to 
normal tissue without significant differences between 3×5 Gy or 3×8 Gy and VMAT or AP/PA (Chi-
square test). 
Abbreviations: NIRV, non-irradiated volume; LDV, low-dose volume; BHDV, bordering high-dose 
volume; HDV, high-dose volume; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-





Neither parameter was notably different between the NIRV and LDV while the frequency was 
somewhat increased for the BHDV, and was drastically raised to higher levels for the HDV. In 
particular, after 3×5 Gy (combined VMAT/AP/PA groups), the yield of tumors in the overall 
HDV was about 3.6 folds and 7.3 folds higher than in the BHDVs and LDVs respectively, 
whereas it was increased dramatically in comparison with NIRV (113.3 folds). A similar trend 
of tumor development was observed in the HDV vs. BHDV, LDV, and NIRV (4.6, 6.7, and 
124.1 folds, respectively) after 3×8 Gy treatment. A comparison by treatment technique (3×5 
Gy/3×8 Gy, combined) showed similar trends: VMAT and AP/PA (4.2, 22.5, 216 folds after 
VMAT, and 3.5, 4.8, 90 folds after AP/PA, for BHDV, LDV, and NIRV, respectively). 
Thus, the frequency of cancerous events per unit volume was increased with increased doses to 
irradiated volume and not with enlarged volume receiving any lower doses in this experimental 
model.  
Notably, no statistically significant difference between the effects of prescribed doses (3×5 Gy 
vs. 3×8 Gy; p = 0.99) nor irradiation technique (VMAT vs. AP/PA; p = 0.84) could be observed 
(Figure R2e).  
Overall, an increased expectancy of tumors was directly associated with higher local doses to 




3.3 Survival in unirradiated and irradiated rat groups  
The observation phase from birth until tumor detection was median 348 [minimum to 
maximum: 175 – 504] days. 
Notably, no animal developed any detectable tumor before attaining an incidence-free age 
border of at least 175 days from birth. Interestingly, this tumor-free time was equally valid for 























Survival of the rats. The Kaplan-Meier survival curves illustrate the declining fractions of living rats 
per time (attained age from birth). (a) No significant differences were observed between Kaplan-Meier 
survival curves of AN and CBCT groups, and (b) groups treated with 3×5 Gy VMAT or AP/PA. (c) The 
curves were significantly decreased for 3×8 Gy groups vs. combined AN/CBCT controls, however, not 
specifically for VMAT vs. AP/PA (d). Gehan-Breslow-Wilcoxon test. 
Abbreviations: AN, anesthesia only controls; CBCT, cone-beam computed tomography only controls; 
VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior irradiation; Gy, 
Gray; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy. Connecting with a slash means combined groups. 
a b 
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Kaplan Meier survival curves, representing the attained age from birth, for control rat groups, 
were similar: median 379 [228 - 499] vs. 364 [205 - 504] days (p = 0.92). Thus, the effect of 
exposure to low doses of CBCT was not detectable in the presented experimental model. 
Therefore, the data belonging to each control group were combined (AN/CBCT) for 
comparison with irradiated groups. 
No statistically significant differences were observed between survival curves for groups 
treated with 3×5 Gy VMAT (p = 0.33) and 3×5 Gy AP/PA (p = 0.223) compared to AN/CBCT: 
median 357 [182 – 451] days for VMAT and 338.5 [208 – 478] days for AP/PA vs. 366 [205 – 
504] days for AN/CBCT (Figure R3b). By contrast, treatment with 3×8 Gy led to a 
significantly shortened lifespan due to earlier tumor appearance in both VMAT and AP/PA 
treated rats (Figure R3c). The difference compared to controls appeared marginally significant 
for VMAT (p = 0.02) and highly significant for AP/PA (p = 0.0005): median 298 [198 – 390] 
days for VMAT and 282 [202 – 390] days for AP/PA vs. AN/CBCT. 
Most interestingly, comparison of the curves for radiation treatment groups, 3×5 Gy and 3×8 
Gy combined, by RT techniques, did not reveal any significant evidence for a specifically 
decreased survival of the rats treated with VMAT compared to AP/PA (median 342 [182 – 451] 
days vs. 305 [202 – 478] days; p = 0.364; Figure R3d). Although not statistically significant, 
a 12% longer median ‘survival’ was observed in rats treated with VMAT vs. AP/PA. 
Taken together, high radiation doses were able to shorten the tumor-prone lifespan in 
Tp53+/C273X rats, without regard to VMAT and AP/PA treatments. These observations 
demonstrated the first in vivo evidence for significantly decreased attained age (that corresponds 
to survival) in the rat groups irradiated with high local doses. 
 
3.4 Dose to volume relationship for the latency time to tumors 
Since the lifespan was shortened for rats from the high-dose groups (3×8 Gy), it was tested how 
far this shortening could be related to different radiation doses delivered to the defined 
irradiated volumes. Detailed analysis of the time span, from the first day of treatment to the 
tumor-related killing of the animals, showed that the TTT for n = 12 tumors found within the 
NIRV in rats treated with 3×5 Gy was quite similar to the TTT of sporadic events in AN/CBCT 
control groups (medians, with minimum to maximum, 295.5 [121 – 359] days vs. 296 [128 – 






























The latency of radiation-induced and spontaneous tumors. (a) Compared to combined controls 
(AN/CBCT), the TTT was significantly decreased for all tumors developing after 3×8 Gy but not 3×5 
Gy. (b) No significant differences in TTT after VMAT vs. AP/PA treatments were observed at either 
dose level (3×5 Gy or 3×8 Gy) for tumors in the LDV/BHDV/HDV. (c) The median TTT was borderline 
significantly reduced for tumors in the LDV (all combined) while it was highly decreased for tumors 
developed within the volumes receiving the highest doses (combined BHDV/HDV). The Mann-Whitney 
test. Plots show individual values and medians. 
Abbreviations: TTT, time to tumor; NIRV, non-irradiated volume; LDV, low-dose volume; BHDV, 
bordering high-dose volume; HDV, high-dose volume; Gy, Gray; AN, anesthesia only controls; CBCT, 
cone-beam computed tomography only controls; VMAT, volumetric-modulated arc therapy; AP/PA, 
anterior-posterior/posterior-anterior irradiation; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy; 
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Similar to the NIRV, n = 17 tumors occurred in the irradiated volume (LDV/BHDV/HDV, 
combined) after 3×5 Gy treatment, did not show a statistically significant decrease in TTT 
compared to sporadic tumors (AN/CBCT): median 258 [137 – 408] days vs. 296 [128 – 484] 
(p = 0.27). 
A significant decrease in TTT compared to AN/CBCT was measured for rats (n = 12) with 
tumors within the NIRV after 3×8 Gy irradiation: median 227 [135 – 297] vs. 296 [128 – 484] 
days, (p = 0.0085). A highly significant decrease in TTT in comparison to AN/CBCT was 
observed, however, in n = 16 rats with tumors in the LDV/BHDV/HDV receiving planned 
doses: median 169.5 [102 – 283] vs. 296 [128 - 484] days, (p < 0.0001). 
Regarding the effects of dose, volume, and radiation modality, no significant difference in TTT 
was detected between tumors that arose within the LDV (3×5/3×8 Gy, combined), 3×5 Gy 
BHDV/HDV, and 3×8 Gy BHDV/HDV after VMAT vs. AP/PA treatment: median 267.5 [218 
– 317] vs. 231 [135 – 259] days (p = 0.57); 292.5 [191 – 380] vs. 257 [137- 408] days (p = 
0.81); and 159 [105 – 202] vs. 149.5 [102 – 283] days (p = 0.933), respectively (Figure R4b). 
A maximum decrease in TTT compared to AN/CBCT revealed for tumors within the 
BHDV/HDV after 3×8 Gy treatment: median 153.5 [102 – 283] vs. 296 [128 – 484] days (p < 
0.0001) (Figure R4c). Next to this, tumors detected in the LDV (3×5 Gy/3×8 Gy, combined) 
also showed a borderline significant reduction in TTT: median 231 [135 – 317] vs. 296 [128 – 
484] days (p = 0.046). 
Possible uncertainties in these comparisons regarding the somewhat older age of some rats in 
3×8 Gy treated groups compared to other groups are discussed below in section 4.6. 
Most importantly, no disadvantages of VMAT vs. AP/PA or enlarged low-dose volume (‘low-
dose bath’) compared to smaller volumes exposed to highest doses were confirmed. 
Furthermore, the most of earliest tumors thereof rather arose in the volumes receiving higher 
doses, unlike lower doses. 
 
3.5 Tumor detection using high-resolution low-dose CT 
In some rats, tumors were recognized as palpable swellings that were not far from the body 
surface (e. g., tumors on the ribs and extremities). Deep-seated tumors (e. g., inside the thoracic 
or abdominal cavity or in the inner organs) were detected by high-resolution CT examination 
using SOMATOM Force CT. 
A list of SOMATOM Force data for each scan is given in Table A6. 
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Bone tumors were easily determined on CT scans, based on skeletal alterations appearing as 
bulged regions, as it is shown in Figure R5a. 
The majority of non-osseous solid tumors could be detected on native CTs as uncommon 
hyperplastic formations or deformed anatomical structures that were abundantly supplied with 
blood vessels and, therefore, more clearly visible in rats receiving an intravenous injection of 
the contrasting media Imeron®-300 before CT scans. 
The representative CT images of rats developing tumors within the HDV are shown in Figure 




















Detection of tumors using clinical CT. (a) A rib bone tumor within the LDV after 3×8 Gy AP/PA 
irradiation (native CT), (b) a native CT of rhabdomyosarcoma in the HDV after 3×8 Gy VMAT, and (c) 
contrast-enhanced (Imeron-300, approx. 2 µl/g body mass) CT of mediastinal rhabdomyosarcoma in 
the HDV after 3×8 Gy AP/PA treatment. Axial, sagittal, and coronal (below) views are shown. Arrows 
indicate the position of tumors. 
Abbreviations: CT, computed tomography; LDV, low-dose volume; AP/PA, anterior-
posterior/posterior-anterior irradiation; HDV, high-dose volume; BHDV, bordering high-dose volume; 
VMAT, volumetric-modulated arc therapy; 3×8 Gy, three fractions of 8 Gray. 
The illustration was published in Sci Rep. 2019 Oct 29;9(1):15489. 
a b c 
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3.6 Entities and the latency of radiation-induced and sporadic tumors 
Based on histopathology, n = 71 index tumors could be assigned to seven different primary 
origins (entities): bone sarcoma, soft tissue sarcoma (rhabdomyosarcoma and fibrosarcoma), 
lymphoma (unclear subtypes), carcinoma (adenocarcinoma or squamous cell carcinoma), breast 
cancer (obviously all carcinomas), malignant mesothelioma, and brain tumors. The entities of 
further n = 13 index tumors described below remained non-determined. 
The estimated entities of tumors are compiled in Table R2 and detailed in Table A7C – J. The 






Tumor entities in rats. Numbers represent index tumors of different entities belonging to control and 
irradiated groups (the volumes of tumor incidence are given in parentheses). 
 
Tumor entities per volume and group BSA SSA LY MM CA BC BT ND 
AN (sham NIRV) 4 0 0 0 3 2 1 3 
CBCT (sham NIRV) 9 1 0 0 1 0 1 2 
3×5 Gy VMAT/AP/PA comb. (NIRV) 4 1 0 0 2 0 0 5 
3×8 Gy VMAT/AP/PA comb. (NIRV) 5 0 0 0 2 1 1 3 
3×5 Gy VMAT (LDV/BHDV/HDV) 3 2 3 1 1 0 0 0 
3×5 Gy AP/PA (LDV/BHDV/HDV) 0 2 4 0 1 0 0 0 
3×8 Gy VMAT (LDV/BHDV/HDV) 0 1 2 1 0 0 0 0 
3×8 Gy AP/PA (LDV/BHDV/HDV) 2 6 3 0 1 0 0 0 
Total 27 13 12 2 11 3 3 13 
 
Abbreviations: BSA, bone sarcoma; STSA, soft tissue sarcoma; LY, lymphoma; MM, malignant 
mesothelioma; CA, carcinoma; BC, breast cancer (all CA); BT, brain tumor; and ND, non-determined; 
AN, anesthesia only controls; CBCT, cone-beam computed tomography only controls; NIRV, non-
irradiated volume; LDV, low-dose volume; BHDV, bordering high-dose volume; HDV, high-dose 
volume; Gy, Gray; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-
anterior irradiation; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy. Connecting with a slash means 
































Representative microscopy images of different tumors. Tumor types (entities) detected in the 
experiment: (a) bone sarcoma, (b) bone sarcoma lung metastasis (osteoid), (c) soft tissue sarcoma 
(rhabdomyosarcoma), (d) soft tissue sarcoma (fibrosarcoma), (e) lymphoma, (f) lymphoma 
(lymphosarcoma), (g) malignant mesothelioma, (h) carcinoma (adenocarcinoma), (i) carcinoma 
(squamous cell carcinoma), (j) brain tumor, (k) non-determined testicular tumor, and (l) non-determined 
pelvic tumor. Shown are microscopy images of 4 – 6 µm thick tissue slices (stained with H&E). Blue-
enriched (oxidized) hematoxylin is due to acidic DNA while proteins are dyed red by eosin. Scale bars: 
200 µm and 50 µm. 
The illustration was published in Sci Rep. 2019 Oct 29;9(1):15489. 
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Bone sarcoma appeared as cartilaginous and ossified masses of tissue that aggressively invaded 
neighboring structures such as muscles, skin, thoracic or pelvic organs and, in some cases, 
metastasized to distant organs (e.g., lungs). Upon microscopic evaluation of the H&E-stained 
tissue slides, bone sarcoma was recognized by an increased occurrence of calcified cell masses 
(inside), and rapidly dividing osteoblasts (many mitotic figures) outwards of the center of the 
tumor mass (Figure R6a). Most bone sarcomas appeared as highly aggressive tumors attacking 
also distant organs. Thus, multiple lung metastases, mostly in form of multiple macroscopic 
osteoids (Figure R6b), found in 5 out of 23 rats with bone sarcomas of the scapula, tailbone, 
femur, tibia, or sacral vertebra. 
The majority (12 of 13) of soft tissue sarcomas were solid tumor masses that originated from 
the muscles and revealed rhabdomyosarcoma morphology. Under the microscope, 
rhabdomyosarcoma cells displayed anaplastic nuclei, scattered mitotic figures, and a few 
apoptotic bodies. Also, one fibrosarcoma was detected as a large, aggressively grown solid 
tumor invading the surrounded thoracic organs and in the liver. Fibrosarcoma cells, commonly 
derived from differentiated fibroblasts, show large nuclei and variable protein rates. 
Representative images of these mesenchymal soft tissue malignancies are shown in Figure R6c 
– d. 
The group of lymphomas (n = 12), a disease that usually can take many forms in animals and 
can spread into almost any tissue in the body, contained tumors aggressively incorporating into 
the neighboring normal tissues. Lymphomas mostly looked like white to slightly yellowish, 
relatively uniform cell masses (clumps), sometimes with necrotic tissues in the center of the 
mass. Under the microscope, these tumors were distinguishable due to lymphocyte-derived 
rounded cell cohorts disseminating into the neighboring normal tissues (Figure R6e – f). 
Two thoracic malignant mesotheliomas were found as relatively large tumors that widely 
occupied the thoracic space and were ingrown in adjacent tissues. Out of further two abdominal 
mesotheliomas, one was invaded in the pancreas and another in the pelvic organs (both NIRV). 
Malignant mesotheliomas were occurred as uniformly formed cell masses attacking normal 
tissues as shown in Figure R6g.  
Carcinomas were represented by lung adenocarcinomas or squamous cell carcinomas with 
intensive proliferated, variably-sized and shaped clusters of arranged epithelial tumor cells 
derived from different organs (Figure R6h – i). 
All three animals with brain tumors showed coordination disorders and problems with 
movement. One tumor was found between the frontal lobes, another one at the cerebellum, and 
a further one was scattered within the cortex and cerebellum. Entities of these brain tumors 
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could not be determined exactly. However, the morphological appearance of these tumors 
argues for sarcoma or gliosarcoma rather than for classical glioma (Figure R6j). 
As mentioned above, the tumor entities could not be exactly specified in some rats developing 
pelvic and abdominal none-osseous tumors: n = 8 (NIRV), n = 3 (AN), and n = 2 (CBCT). 
These tumors were assumed as tumors with non-determined entities. Exemplary images of such 
non-determined, testicular and pelvic tumors are shown in Figure R6k – l. 
In n = 11 rats one or more tumors of a different type (entity) were found in addition to the index 
tumor. These malignancies were not included in the analysis of index tumors. The entities and 
the locations of additional tumors are given in Table A8.  
Tumors of the same entities were grouped by their appearance in the different dose volumes 
and compared to indicate whether a particular tumor entity might be typical of unirradiated or 
irradiated body parts. In addition, it was tested, whether any type of found tumors could be 
specific for low dose volumes or high dose volumes. Upon evaluation of sporadic tumors in 
control rats and tumors from the NIRV, no lymphoma was detected, whereas the most frequent 
tumors were bone sarcoma (n = 22) or carcinoma (n = 8). Other tumors entities like soft tissue 
sarcoma (n = 2), malignant mesothelioma (n = 2), breast cancer (n = 3), and brain tumors (n = 
3) were rare (Table R2 and Figure R7a). In contrast to NIRV, lymphoma (n = 12) and soft 
tissue sarcoma (n = 11) were the most frequently detected tumors in the irradiated volume while 
bone sarcoma (n = 5), malignant mesothelioma (n = 2), and carcinoma (n = 3) were also found. 
Thus, lymphoma (p < 0.0001) and soft tissue sarcoma (p = 0.0001) were strongly associated 
with irradiated volume in contrast to bone sarcoma detected predominantly in NIRV. 
Interestingly, the shortening of the TTT for malignancies after 3×8 Gy vs. 3×5 Gy treatment 
was not associated with either tumor entity (Figure R7b). An exception was lymphoma, with 
a decreased median TTT after 3×8 Gy compared to 3×5 Gy: 143 [102 – 202] vs. 258 [154 – 




































Tumors grouped by their entities and occurrence in different volumes. (a) BSA predominantly, but 
no LY, and only two STSA were detected in AN/CBCT controls and the NIRV of irradiated rats. In 
contrast, LY was exclusively, and STSA was specifically developed in the irradiated volume 
(LDV/BHDV/HDV) and bone sarcoma in the NIRV (Fisher’s exact tests). (b) Median TTTs were not 
significantly different between tumor types after either dose treatment, while it was reduced only for LY 
developed in the volume irradiated with 3×8 Gy vs. 3×5 Gy (Fisher’s exact test). Received dose levels 
for each groupe are shown. See also Table R2. 
Abbreviations: BSA, bone sarcoma; CA, carcinoma, STSA, soft tissue sarcoma; BT, brain tumor; BC, 
breast cancer; LY, lymphoma; MM, malignant mesothelioma; ND, not determined; TTT, time to tumor; 
AN, anesthesia only controls; CBCT, cone-beam computed tomography only controls; NIRV, non-
irradiated volume; LDV, low-dose volume; BHDV, bordering high-dose volume; HDV, high-dose 
volume; Gy, Gray; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy. Connecting with a slash means 
combined volumes or groups. 
 



















































































3.7 Loss of Tp53+/C273X heterozygosity in radiation-associated and sporadic tumors 
From the idea that radiation-associated tumor development might be driven by the loss of intact 
Tp53 allele (LOH), n = 40 index tumors from irradiated and non-irradiated rats were genotyped 
for the presence of mutations in Tp53 gene core fragment (Table A7K – L).  
To test whether the missed second intact Tp53 allele (LOH) could be associated with radiation, 
tumors were grouped either by the volume of their origin (irradiated or unirradiated), initially 
prescribed doses (3×5 Gy or 3×8 Gy), or used dose delivery technique (VMAT or AP/PA). The 
analysis revealed no notable difference between the fractions of tumors with and without LOH 
developed in controls (8 of all tested 11), in the NIRV (4 of 12), or in LDV/BHDV/HDV (10 
of 17) (Table R3). 
Interestingly, in all tumors, LOH showed the same T/A mutation, and no other gained sequence 
changes in tested Tp53 fragments were found. Representative PCR products and sequencing 
chromatograms for different rat Tp53 genotypes are shown in Figure R8. 
A further comparison of the tumor genotypes (Tp53+/C273X or LOH) indicated that LOH was not 
specifically appeared in tumors developed within the irradiated volume (10 of 17 in irradiated 










Sham-NIRV NIRV LDV/BHDV/HDV 
< 0.04 Gy 3×5 Gy 3×8 Gy 3×5 Gy 3×8 Gy 
LOH 8 3 1 3 7 
Tp53+/C273X 3 2 6 5 2 
 
Abbreviations: LOH, loss of heterozygosity; Tp53+/C273X, heterozygous for Tp53; AN/CBCT, combined 
controls receiving anesthesia/cone-beam computed tomography only; NIRV, non-irradiated volume; 
LDV/BHDV/HDV, entire low-dose, bordering high-dose, and high dose volumes; Gy, Gray; 3×5 Gy or 



























Fig. R8. Genotyping of normal and tumor Tp53. (a) PCR copies of 834 bp spanning Tp53 and 240 
bp Gapdh DNAs alongside negative controls (MMs)*. (b) A purified 834 bp PCR product before 
sequencing. (c) A 4523 bp spanning Chr10 amplicon from tumor gDNA with derived 2752 bp nested 
PCR product, and a 240 bp tumor Gapdh. (d) Nested PCR product with 2650 bp length amplified from 
4523 bp PCR product. Typical sequencing chromatogram fragments for (e) Tp53C273/C273, (f) 
Tp53C273X/C273X, and (g) Tp53+/C273X. (h) LOH (Tp53C273X/C273X) in a tumor expressed as a strongly 
declined T-peak compared to A (the small T level may refer to tumor-adjacent residual normal tissue). 
Numbers above the nucleotide sequences represent readable base positions. 
Abbreviations: gDNA, genomic DNA; M, marker; bp, base pair; Tp53, Tumor protein 53; Gapdh, 
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LOH analysis in tumors. (a) LOH was similarly occurred in tumors detected in irradiated 
(LDV/BHDV/HDV) and unirradiated (AN/CBCT/NIRV) body regions and no statistically significant 
differences in proportions of radiation-induced tumors with and without LOH in the LDV/BHDV/HDV 
between (b) 3×5 Gy and 3×8 Gy or (c) VMAT and AP/PA treated rats. (d) Analysis of different index 
tumors with and without LOH. e) LOH was more specific for sarcoma (BSA/STSA) compared to all 
other tumor types combined (Fisher’s exact test). 
Abbreviations: LOH, loss of heterozygosity; Tp53+/C273X, heterozygous for Tumor protein 53; BSA, bone 
sarcoma; CA, carcinoma, STSA, soft tissue sarcoma; BT, brain tumor; BC, breast cancer; LY, 
lymphoma; MM, malignant mesothelioma; ND, non-determined; AN, anesthesia only controls; CBCT, 
cone-beam computed tomography only controls; NIRV, non-irradiated volume; LDV/BHDV/HDV, 
low-dose, bordering high-dose, and high dose volumes combined; Gy, Gray; 3×5 Gy or 3×8 Gy, three 
fractions of 5 or 8 Gy. Connecting with a slash means combined volumes, rat groups, or tumor entities. 
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LOH in tumors developed in the LDV/BHDV/HDV could not be specifically associated with 
prescribed total doses (3 of 8 tumors after 3×5 Gy vs. 7 of 9 tumors after 3×8 Gy, p = 0.15; 
Figure R9b) or with VMAT or AP/PA treatments (4 of 7 tumors after VMAT vs. 6 of 10 tumors 
after AP/PA, p = 1.0; Figure R9c).  
Interestingly, most soft tissue sarcomas (6 out of 7) and bone sarcomas (9 of 11) revealed LOH 
in contrast to other tumors (7 of 22, p = 0.0015; Figure R9d – e).  
A comparison of the median latency TTT and lifespan of n = 18 rats with Tp53+/C273X tumors 
with corresponding median values of n = 22 rats with tumors with LOH resulted in slightly 
reduced values for animals with tumors containing LOH led to slightly reduced values for 
animals with tumors with LOH, compared to those with heterozygous Tp53+/C273X tumors 
















LOH and the latency of tumors. The Kaplan-Meier survival curves represent the proportions of living 
rats that decrease over time. (a) The median latency TTT from treatment of tested n = 22 rats developing 
tumors with LOH was somewhat but insignificantly shortened vs. rats developing tumors with 
Tp53+/C273X genotype (n = 18). (b) A similar trend shown in (a) was detected for attained days (full 
lifespan). 
Abbreviations: LOH, loss of heterozygosity; TTT, time to tumor; Tp53+/C273X, heterozygous for Tumor 
protein 53. 
An analogous illustration was published in Sci Rep. 2019 Oct 29;9(1):15489. 
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Thus, the median TTT for tumors with LOH was 45.5 days shorter in comparison to tumors 
with Tp53+/C273X: 249.5 [135 – 380] days vs. 295 [134 – 417] days, (p = 0.12). Accordingly, 
also the median lifespan was shortened by 36 days for tumors with LOH vs. Tp53+/C273X: 395 
[222 – 499] days vs. 323.5 [216 – 451] days (p = 0.12). Therefore, no significant difference 
between the latency of tumors with and without LOH could be observed.  
 
3.8 Inflammatory alterations in irradiated and unirradiated rat lungs 
Testing whether the malignant effects of radiation in rats could be influenced by radiation-
specific inflammatory late alterations in irradiated thoracic volumes, several H&E-stained 
histology slides from thoracic organs were examined (Table A7M).  
The numbers of rats with and without inflammatory events in the lungs are given in Table R4. 
Pathological examination of the thoracic tissue samples derived from the rats with tumors 
outside the thoracic region indicated predominant pulmonary inflammatory changes – multiple 
microscopic inflammatory foci appeared as agglomerated lymphocytes scattered into the 






Inflammation in the lungs: scored as none (0), rare (1), moderate (2) and frequent (3) grade events. 
 
Events per group Grade 0  Grade 1 Grade 2 Grade 3 Total 
AN 2 4 2 3 11 
CBCT 3 2 6 0 11 
VMAT 3×5 Gy  1 1 1 0 3 
AP/PA 3×5 Gy  3 1 0 0 4 
VMAT 3×8 Gy  1 5 3 0 9 
AP/PA 3×8 Gy  1 1 1 0 3 
 
Abbreviations: AN, anesthesia only controls; CBCT, cone-beam computed tomography only controls; 
NIRV, non-irradiated volume; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-































Inflammation in irradiated and unirradiated lungs. (a) Microscopically small inflammatory clusters 
in a tumor-free lung at a segmental bronchus. Arrows indicate the lymphocyte foci. H&E stain. Scale-
bars: 500 μm and 50 µm. (b) Inflammation (any grades 1 – 3) was similarly detected in irradiated (3×5 
Gy/3×8 Gy) and unirradiated (AN/CBCT) rat lungs (Fisher’s exact test). (d) No significant connection 
of VMAT to inflammation, compared to AP/PA, was detected (Fisher’s exact test). Connecting with a 
slash means combined groups or combined inflammation grades. 
Abbreviations: AN, anesthesia only controls; CBCT, cone-beam computed tomography only controls; 
VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior beams; Gy, 
Gray; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy.  




















































No notable relationships between inflammation and irradiated volume or VMAT and AP/PA 
treatment could be detected in this experiment (R11b – c). Thus, both presence and absence of 
recognizable inflammation of any grade (1 – 3) were not significantly different between 
unirradiated and irradiated rats (n = 17 and n = 5, AN/CBCT vs. n = 13 and n = 6, 3×5 Gy/3×8 
Gy respectively; p = 0.73). These events were also not significantly different for the rats treated 
with VMAT compared to AP/PA (n = 10 and n = 2 vs. n = 3 and n = 4, presence and absence 
respectively; p = 0.13).  
 
3.9 Sex-associated features of tumors 
The next question that was derived from the results obtained was, whether the malignant effects 
of radiation could be influenced by individual parameters such as sex. It was mentioned above 
that sex is related to the size of the rats and therefore to the size of the irradiated and non-
irradiated volumes (see Table M3 and Table M4).  
There was no difference between the numbers of female and male rats in terms of the yield of 
tumors in NIRV or combined LDV/BHDV/HDV (Figure R12a). 
The median TTTs in female and male rats developing tumors within the irradiated 
LDV/BHDV/HDV after irradiation with small or large radiation plans respectively were 
insignificantly (p = 0.17) different:  231 [134 – 408] days vs. 201 [102 – 322] days for n = 15 
females and n = 18 males (Figure R12b). However, soft tissue sarcoma was frequent and 
lymphoma - rare in female rats, while inversely, fewer soft tissue sarcomas and more 
lymphomas were found in male rats: n = 18 sarcomas and n = 3 lymphomas compared to n = 2 
sarcomas and n = 9 lymphomas (p = 0.0048) (Figure R12c). 
An additional comparison of the median latency TTT for female sarcoma with corresponding 
TTT for male lymphoma resulted in an insignificant difference: 239 [134 – 380] days vs. 210 
[102 – 298] days (p = 0.52), respectively (Figure R12d). 
Taken together, the incidence of sarcoma and lymphoma within the volume exposed to highest 
doses in this experiment were coupled with female and male sex respectively while no notable 


























Some sex-linked traits of tumors. (a) Tumor development in irradiated and unirradiated volumes in 
female and male rats was not notably different. (b) No significant difference between median TTTs of 
radiation-associated tumors in female vs. male rats detected. (c) Significantly more LY than STSA were 
found in male rats in comparison to female rats that predominantly developed STSA. (d) No significant 
difference between TTTs for female STSA and male LY were detected.  
Abbreviations: XX, females; XY, males; NIRV, non-irradiated volume; LDV/BHDV/HDV, low dose-, 
bordering high dose-, and high dose volumes combined; TTT, time to tumor; LY, lymphoma; STSA, 
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4.1 State of the art and aim of the study 
There are prognostic studies predicting a worldwide increase in cancer incidence in the future 
116,117. Consequently, an increasing number of cancer patients will receive RT, also because of 
the increasing availability of RT centers worldwide. Due to improvements in oncology, and 
especially in RT, the rate of patients surviving cancer will be much higher in the future than 
ever before. Accordingly, the overall incidence of radiation-associated SC could rise with the 
increasing number of cancer survivors who underwent RT. Hence, it is becoming increasingly 
important to reduce the risk of radiation-associated SC. 
There is an experimentally unproven dogma that IMRT can increase the risk of SC compared 
to 3D-CRT. Modern IMRT techniques are consequently avoided in many cases because of 
supposed disadvantages of low doses that conflict recommended reduction of unwanted high 
doses to normal tissue for prevention of radiation-related side effects. 
The assumption of an additional increase in SCR after multi-beam IMRT, compared to 3D-
CRT, have been estimated due to the longer irradiation time that IMRT requires to deliver the 
same radiation dose to the target volume than conventional 3D-CRT. Longer exposure times 
correlate with increased exposure to secondary low radiation doses (integral doses), and 
extended integral doses may increase the dose-response, especially in young RT patients 54-58. 
However, the modern high-speed VMAT technique can reduce integral doses, due to advanced 
planning drafts, compared to older multi-beam IMRT. 
In contrast to low doses, conventional 3D-CRT delivers more unwanted high doses to normal 
tissue than modern IMRT, and therefore, can even increase the dose-response (toward adverse 
effects including SC) as recognized by retrospective epidemiological studies 80,82,84,118.  
It is consistent with clinical findings indicating that the risk of SC and other normal tissue 
complications decreases in childhood cancer survivors over the last decades with increased RT 
conformality 31,40,45. Therefore, a reduction in the volume of normal tissue receiving high doses 
by high-conformal IMRT techniques, could even decrease the risk of SC. So, withholding 
modern IMRT techniques from patients because of the suspected disadvantages of a low-dose 
may increase the risk of side effects associated with high doses. 
At the time of this study, no in vivo results were available that investigated to what extent 
different RT modalities can positively or negatively influence the risk of radiation-associated 
SC. The present study provides the first experimental evidence that SCR may increase with 
increased radiation dose to normal tissue and not specifically after IMRT vs. 3D-CRT (VMAT 
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vs. AP/PA), at least in a cancer-prone rat model. Since the presented experiment was a single 
study, more translational studies have to be done that may lead to a reevaluation of the common 
practice of withdrawal modern IMRT techniques from juvenile patients especially. 
 
4.2 Relationships of radiation dose and RT technique to tumor development 
At the beginning of the experiment, it was expected that radiation-induced tumors would occur 
within the irradiated body volume of rats and sporadic tumors within the NIRV. Since all 
sporadic tumors in controls were detected within the sham-NIRV and n = 33 treated rats 
developed tumors in the irradiated thoracic volume, tumors that developed in the sham-NIRV 
and NIRV were assumed to be spontaneous, and the tumors found in the irradiated volume 
assumed as radiation-induced or, at least, associated with radiation. 
The AN control group was not exposed to any radiation other than follow-up CT scans and 
aimed to be a unirradiated reference group. The CBCT control group was used in the experiment 
to assess any possible effect of very low doses applied to rats during positioning on LINAC. In 
the absence of an accurate dosimetry method for calculating the radiation doses to which the 
rats were exposed during the CBCT scan, the CBCT fraction dose was roughly estimated at 
approximately 0.04 Gy per cm3 exposed volume, according to the manufacturer's information. 
Therefore, rats belonging to this control group were exposed to cumulatively estimated doses 
of about 0.12 Gy during 3×CBCT-positioning, similar to those from radiation treatment groups. 
As illustrated in Figure M5b, the cone-beam covers almost the entire body of the rat from the 
head to the pelvic area. Thus, these CBCT doses are approximately comparable to the whole-
body doses to which Japanese ABS were exposed. Since no notable differences in tumor 
incidence sites and TTTs were recognized between AN and CBCT controls, the rat model with 
applied experimental settings was unable to show any response to very low doses.  
Modeling of radiation-induced carcinogenesis generally assumes a linear DRR in the low-dose 
region reaching saturation at higher doses 74,77,119-121. The main uncertainty in SCR prediction 
bases on the dogma that 3D-CRT will lead to lower risk compared to IMRT. It rests on the 
assumption that the DRR increases linearly approximately between 4 – 8 Gy received doses 
with no further increase at higher doses 66,120. This is explained by the proposed theory that 
exposed cells could survive low doses and cause SC while being sterilized by higher doses. The 
results obtained from the presented experiment, in contrast, do not confirm the increase in tumor 
induction in the tissues receiving lower doses compared to higher doses and are rather consistent 
with the results of epidemiological studies on cancer survivors assuming a linearly increase in 
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dose-response to RT for second sarcomas, basal cell carcinoma, meningioma, salivary gland 
cancer, glioma, breast cancer 80,122,123. The predominant development of irradiated volume-
associated tumors (23/33) in the HDV (receiving 13.5 – 15 Gy or 21.6 – 24 Gy) in the 
experiment further mirrors the evidence of clinical studies showing that most SCs after RT 
develop near the edge or inside the PTV and only approximately 20% in tissues receiving lower 
doses 15,84. 
As indicated in Table A4 and illustrated in Figure R3, the frequency distribution of tumors 
(the ratio of events per unit volume) was much higher in smaller-sized HDVs than in larger 
BHDVs and LDVs, without the specific influence of VMAT vs. AP/PA.  
Most notably, no increased response to VMAT compared to AP/PA was observed with regard 
to radiation-induced tumor development, and therefore, no disadvantages of IMRT compared 
to 3D-CRT could be recognized. 
 
4.3 Latency time of tumors related to local high-dose irradiation 
In the experiment, an incidence-free follow-up period of at least 175 days was observed in 
which no detectable tumors occurred in any of 84 rats (both control and irradiated). A most 
simple, but indeed plausible explanation could be that aging determines the incidence time of 
tumors in these heterozygous rats. After translating the lifespan of rats into the lifespan of 
humans, the incidence-free follow-up period of 175 days in rats is comparable to around 12.7 
years in humans because 13.8 days of life in rats correspond to one year of life in humans 124,125. 
Thus, the tumor-free period in rats actually appears as translatable to a long-term SC-free period 
in humans, indicating that the animal model used in this study was suitable for studying the 
long-term response to high-dose radiation. 
As expected previously, radiation-associated tumors may have some specific features that differ 
from sporadic tumors. At the end of the experiment, there was evidence found that the lifespan 
of some rats was shortened due to the decreased TTT latency for malignancies within the HDV 
exposed to the highest target dose (Figure R3 and Figure R4). 
Most importantly, the observed decrease in lifespan in 3×8 Gy treated rats was not stronger 
associated with VMAT than AP/PA since a median 16 days longer lifespan (282 days) after 
treatment with VMAT than AP/PA detected, compared to controls. According to the translation 
of the lifespan from rats to humans, every rat day equals approximately 34.8 human days, as 
described in Sengupta et al 125. This could mean that the median lifetime after VMAT was by 
about 1.52 human years (557 human days) longer in contrast to AP/PA. Albeit such a 
DISCUSSION 
68 
hypothetical translation may not seem plausible for RT professionals, the trend remains still 
conceivable. Thus, reducing undesirably high doses to normal tissue using IMRT could at least 
hypothetically postpone the development of SCs at later time points.  
Since shortened lifespan and TTT in 3×8 Gy treated groups were caused by a specific decrease 
in TTT values for soft tissue sarcomas and lymphomas occurring within the HDV after 3×8 Gy 
treatment, the early development of these tumors could be directly associated with high doses 
and, correspondingly, with the increased response of tissues exposed to high doses. However, 
this does not imply that tissues that receive low doses had been protected against the 
development of radiation-related tumors. Even cumulative doses between 7.5 Gy and 12 Gy are 
more likely to cause cancer in this animal model, but such LDV tumors cannot be detectable 
due to the killing of the animals developing earlier sporadic or HDV tumors. Indeed, some 
irradiated animals euthanized also because of spontaneous tumor development. Otherwise, 
these animals might someday develop radiation-induced tumors in the LDV, HDV, and HDV.  
It should be noted that the initial Tp53+/C273X heterozygosity in the original rat line was 
associated with shortened telomeres and decreased telomerase activities, but also prolonged 
tumor latency, in contrast to Tp53C273X/C273X homozygosity leading to early malignancies having 
longer telomeres 124. This implies the hypothesis that the telomere context could have an impact 
on radiation carcinogenesis. In particular, studies of telomeres in radiation-induced and 
spontaneous tumors can provide interesting information about the telomere context in the case 
of radiation-induced shortening of the latency of Tp53-mutated tumors.  
Interactions between radiation doses and genetic conditions in radiation carcinogenesis are 
interesting research subjects for which further experiments could address this problem. 
 
4.4 Characteristics of radiation-associated and sporadic tumors 
Radiation-related and sporadic tumor entities 
Because both cumulatively applied doses (15 Gy and 24 Gy) in the experiment were responsible 
for the induction of radiation-associated tumors within the irradiated volume and a shortening 
of the TTT after 3×8 Gy irradiation was observed, it was questioned whether these effects could 
be specifically related to the recognized tumor entities. The hypothesis was that the entities 
might differ between tumors in differently irradiated and unirradiated volumes. Pathological 
examination of tumors detected in the experiment demonstrated that bone sarcoma and 
carcinoma were developed predominantly in the NIRV and sham NIRV, while all lymphoma 
and most soft tissue sarcoma were associated with the irradiated volume. 
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In the studies by van Boxtel et al 108 and Hermsen et al 124, most of the sporadic tumors in 
Tp53+/C273X rats were either bone sarcoma or soft tissue sarcoma whereas no carcinoma was 
detected. Unlike this, half of all sporadic tumors in another heterozygous Tp53tm1[EGFP-pac] rat 
line were lymphomas, while about a quarter of detected tumors were hemangiosarcomas and 
breast cancers, while sarcomas rarely occurred 110. The homozygous rats of mentioned both 
lines mostly developed hemangiosarcomas but rarely also fibrosarcomas, rhabdomyosarcomas, 
B-type lymphomas, carcinomas, and some very rare non-determined tumors. These facts 
indicate that the spectra of sporadic tumors could vary between rats carrying different Tp53 
mutations. 
The data obtained by the presented experiment show, however, no evidence of a sporadic 
specificity of lymphomas and soft tissue sarcomas (mostly rhabdomyosarcoma). Indeed, the 
specific appearance of lymphoma and sarcoma in irradiated body volumes (receiving doses of 
at least 13.5 Gy – 24 Gy) indicates the specific association of these tumor entities with high 
radiation doses. These translational findings are rather consistent with retrospective clinical 
data, showing the association of the second lymphoma and soft tissue sarcoma with volumes 
irradiated with high RT doses 80,82-85. 
Out of all n = 31 bone sarcomas in the study, two were developed at the vertebra, two at the 
ribs, and one at the sternum in irradiated rats, while nine were found in the NIRV, nine in CBCT 
controls, and four in AN control group (Table A7B – C). Apparently, bone sarcoma was a 
highly metastatic tumor in p53 insufficient rats since the development of pulmonary metastases 
was observed in the presented experiment (Figure R6a – b). Sporadic bone sarcoma was also 
found in other Tp53+/C273X and Tp53tm1[EGFP-pac] rats mentioned above. Although five index and 
four additional bone sarcomas detected in the irradiated volume, this tumor type could not be 
truly associated with radiation. Since bone sarcoma predominantly occurred in NIRVs and 
controls in the presented experiment, and also in the studies by van Boxtel and Hermsen et al, 
that could be mostly assumed as sporadic tumors in this rat line. However, in patients, also 
second bone sarcomas have been evidently associated with high radiation doses 80.  
Malignant mesothelioma is a relatively uncommon tumor in labor rats, but it was also found in 
the experiment. In particular, index mesotheliomas were detected in the mediastinum of two 
rats, one irradiated with 3×5 Gy VMAT (BHDV) and another with 3×8 Gy VMAT (HDV), but 
also in the NIRV, additionally to carcinomas, in the abdomen of two rats receiving anesthesia 
only (Table A7B, F). Therefore, it is not clear whether these mesotheliomas were surely related 
to radiation. However, it is to note that the second mesotheliomas were rarely detected within 
the large cohort of patients cured with RT against HL or non-HL 125. 
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There is no plausible reason to associate found carcinomas with radiation, as eight of these 
epithelial malignancies have occurred in parts of the body distant from the chest volume and 
only three cases were found in irradiated lungs. This either indicates that carcinomas can be 
only marginally associated with radiation, or the animal model and the methods used in this 
experiment were limited to study radiation-induced epithelial tumors. Moreover, the 
development of second carcinomas could be a species-specific sign of humans but not of rats 
used in the presented study.  
The tumor developing sites in the animals of this study are given in Table A7B. Most of the 
tumors in control animals and in the NIRV of irradiated animals were developed at specific 
body parts such as limb bones or pelvic organs. These body parts may have an elevated cancer 
risk than other sites.  
The primary origin of evidently non-osseous tumors, developed outside the thoracic volume in 
control and irradiated rats (n = 5 and n = 8, respectively), could not be determined exactly with 
H&E histology only. Additional tests on tumors using antibody-based immunohistochemistry 
can provide more information about the exact subtypes of these malignancies. 
Taken together, there was a clear difference between the entities of tumors from irradiated and 
non-irradiated volumes. Thus, the development of lymphoma and soft tissue sarcoma was more 
likely related to irradiation, while bone sarcoma, malignant mesothelioma, carcinoma, breast 
cancer, brain tumors, and other non-determined tumors appeared to be sporadic tumors.  
The next interesting topic was to review the possible relationship between a particular tumor 
type and corresponding TTT. 
It must be mentioned again here that most of the rats remained tumor-free over a long period, 
without any detectable behavioral or conditional abnormalities during this time. Sick animals, 
by contrast, showed more than 10% weight loss of attained body masses and displayed several 
abnormalities of the general condition, coordination, activity, food and water uptake, or social 
behavior. These symptoms (not always all of them) appeared in rats a few days before tumors 
were discovered.  
The TTTs could be possibly influenced by the entities of occurred tumors because some tumor 
types probably could tend to develop or grow more rapidly than the others. Therefore, the 
observed shortening of the TTT after a cumulative dose of about 24 Gy for tumors developed 
in HDV could be influenced by certain tumor entities. In addition, it should not be 
underestimated that the individual predisposition of rats to earlier cancer development 




In order to closely study the developmental properties of tumors at the cellular and molecular 
level, further investigations of the tumor samples are required. For example, a comparison of 
the activity of the marker of proliferation Ki-67 in tumor samples may provide evidence about 
the velocity of the tumor development in rats because Ki67 is an established marker of tumor 
growth, in particular for breast cancers in women 126-128.  
An interesting trait of radiation-associated lymphomas in the experiment was the significantly 
earlier (by median 115 days) appearance in the HDV after 3×8 Gy compared to 3×5 Gy, as 
described in section 3.6 and shown in Figure R7b. This observation indicates that high 
radiation doses promote the early development of radiation-associated lymphoma in p53 
insufficient rats. Anyway, a significant shortening of the TTT after 3×8 Gy irradiation was an 
effect of cumulatively received the highest doses that were responsible not only for the 
induction of radiation-associated tumors in the HDV but also suitable to shorten the latency of 
these tumors.  
The findings concerning tumor entities are limited to some extent by restricted sample sizes. 
Further studies have to be conducted to verify the obtained research results. Expanding the 
groups of experimental subjects could possibly achieve greater statistical significance and thus 
clearer results. Indeed, a detailed characterization of radiation-related tumors in preclinical 
models could have important translational relevance for radiation-induced SC research.  
LOH in radiation-related and sporadic tumors 
The likelihood of spontaneous tumor development in mammals increases with Tp53 
insufficiency because the Tp53 gene protects mammals from cancer, primarily through its role 
in cell cycle control, DNA repair, and apoptosis-mediated cell death 100,106,129,130. Consequently, 
TP53 mutations are found in approximately half of all and, mainly, in highly aggressive 
metastatic human tumors 94,131. Loss of Tp53 leads to dissemination and migration and, 
therefore, to tumor cell aggressiveness triggered by downregulation of cell adhesion signaling 
pathways 132,133. Under these circumstances, LOH of Tp53+/C273X heterozygosity in rats may 
also result in an aggressive growth of tumors in rats. As detected in the experiment, at least 57% 
of all tested n = 40 tumors had LOH (Table R3 and Figure R9). This data appears to be at least 
partially consistent with results reported by van Boxtel et al 108 and Hermsen et al 124 as LOH 
was detected in almost all (22 of 23) sporadic tumors (in both reports combined).  In line with 
this, almost all tested bone and soft tissue sarcomas (83%, 15 of 17 combined) displayed LOH 
of the Tp53 gene, in contrast to about a third (31.8%, 7 of 22) of all other tumors in our study. 
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It indicates that both bone and soft tissue sarcomas were highly prone to Tp53+/C273X LOH 
relative to other tumors.  
A study comparing the hyper-reactivity of CpG dinucleotides between sporadic und radiation-
related human tumors reveals evidence for specificity of TP53 mutational ‘hot spot codons’ 
134, 135, and 237 for radiation tumorigenesis in contrast to codons 175, 248, 273, 282, and 
245, that are frequently found in human sporadic tumors 97. In the present study, however, none 
of the homologous of these mutations recognized in tested tumors besides Tp53+/C273X shown 
in Figure R8h. Despite this, it is unknown whether other radiation-induced mutations than 
Tp53C273X/C273X LOH were involved in the tumorigenesis in this experiment. 
In summary, LOH was not associated with radiation generally, with any lower or higher target 
doses (3×5 Gy or 3×8 Gy) as well as with irradiation modality (VMAT or AP/PA). More likely, 
LOH was of the same origin (C273X) in spontaneous and radiation-associated tumors. This 
may indicate that the Tp53C273/X LOH was rather spontaneous than radiation-induced.  
 
4.5 Inflammatory alterations in irradiated and unirradiated tumor-free lungs 
The development of SC in RT patients seems certainly not only due to the residual DNA 
damage that has occurred in a single cell. A study dealing with cancer evolution across the tree 
of life reports that cancer is generally characterized by a breakdown of the central features of 
the multicellularity, including proliferation, cell death, division of labor, resource allocation, 
and, extracellular environmental maintenance 134. Presumably, there are various intrinsic and 
extrinsic causative factors acting over many years to establish a pre-cancerous environment, 
promoting SC in cancer survivors. Other findings have demonstrated that the quality of the 
changes in micro- and systemic- environments may promote radiation carcinogenesis135-137. 
Thus, the microenvironment appears to play an important role in promoting radiation dose-
dependent effects that can emerge due to the anti-inflammatory effect of low doses 138 or pro-
inflammatory effects caused by high doses 139. Therefore, radiation used in the experiment 
could have caused some radiation-induced abnormalities, such as inflammation or fibrosis, 
paving the way for radiation-induced tumor development in irradiated normal tissues. So, it has 
been hypothesized that radiation can trigger SC development via determining the late effects 
within the irradiated normal tissue. 
To recognize detectable non-neoplastic alterations in tumor-free lungs and mediastinal tissues, 
non-irradiated and irradiated tumor-free thoracic organ samples were examined by microscopy. 
However, this test revealed no significant differences in the number of inflammatory foci 
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between irradiated and unirradiated rat lungs or lungs exposed to different target doses (3×5 Gy 
or 3×8 Gy) or dose delivering techniques (VMAT or AP/PA) (Figure R11b – c). The lower 
incidence after AP/PA, in contrast to VMAT, relates there to a lower number of rats with tumor-
free thorax after AP/PA treatment. Moreover, no other alterations, such as typical radiation-
associated pneumonitis and/or fibrosis detected among these samples.  
In general, inflammation in the tumor-free lungs of tested rats could not be specifically linked 
to radiation and, thus, also not with radiation-induced tumor development.  
 
4.6 Study design 
Animal model  
As introduced above, only a small fraction of second primary cancers being considered 
radiation-induced in RT-treated cancer survivors.  In line with this, wild-type rats are not well 
compatible for radiation-induced carcinogenesis experiments since the rate of expected 
radiogenic tumors would be very low and scarcely detectable in these animals. Since Tp53 
mutant rats develop spontaneous tumors, they should also be prone to radiation-induced cancer. 
Indeed, the detection of radiation-associated tumors in this experimental setup was only 
possible due to the susceptibility to tumors caused by the Tp53 mutation. It was also taken into 
account that, due to earlier tumor development, homozygous rats have a very short life 
expectancy compared to wild-type and heterozygous animals 108,124. For these reasons, 
functionally p53-haploinsufficient heterozygous rats, with expected longer survival than 
homozygous ones, were preferred for the experiment. Indeed, the Tp53+/C273X rat model was 
quite well suited to study the dose-response relationships of local irradiation and radiation-
induced tumor development. 
As mentioned above, cancer-prone Tp53+/C273X rats are haploinsufficient for p53 owing to a 
nonsense mutation in one of the Tp53 sister alleles. This genetic condition mimics the genetic 
background of LFS in humans, as both rats and humans develop spontaneous tumors of various 
entities. In addition, specific point mutations have been found in LFS families that, due to their 
position within the TP53 gene appear to be functionally similar to C273X of Tp53 gene in rats. 
Due to evolutionary conservation, there are actually not large differences between DNA 
sequences of the core DNA-binding domain of the rat Tp53 and human TP53 genes. An 
example of a Tp53 core fragment conserved evolutionary between humans and rats is shown in 
Appendix (Sequence Information A1 – A2). 
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In Tp53+/C273X rats, codon C273 of the Tp53 gene corresponds to codon 275 in human TP53. 
The neighboring mutational ‘hotspot codons’ H273 and R282 are similar to C273X in rats and 
frequently found in human tumors, including tumors in persons with LFS 102. All these 
mutations are located within the same central fragment of the gene (rat exon 6 and human exon 
8, respectively), encoding the core DNA-binding protein domain. Accordingly, the Tp53+/C273X 
haploinsufficiency in the experimental animal model increases the likelihood of radiation-
associated cancer development similarly to LFS families. However, even small differences 
could influence the functions of genes. About 30% of mutations in human tumors, recorded in 
the somatic mutation database of the international agency for research on cancer – IARC, are 
missense mutations 97,104. In contrast, C273X is a nonsense mutation, which does not result in 
a detectable truncated p53 protein in rats because of nonsense-mediated mRNA decay 108, while 
the missense mutations may result in new proteins with aberrant activities 93,94,140. Thus, the 
Tp53C273X mutation causes a real p53 insufficiency in the presented rat model, without possible 
residual effects of a truncated p53 variant.  
Animal experiments are indispensable in biomedical research to examine very complex 
processes in a living system. At the same time, limiting the number of test animals to a necessary 
minimum is a prerequisite for the approval of an animal experiment by the competent 
authorities. As a guideline, the ethical principle of 3R [replace, reduce, refine] coined by 
William Russell and Rex Burch in 1959 should be implemented 141. Since the aim of the 
experiment was to compare the number of rats developing radiation-induced malignancies 
between non-irradiated control groups, a sufficient number of control animals were required. 
In particular, for the Kaplan-Meier survival analysis, at least 12 – 14 animals per group is 
required, as described in Yan et al. 110. Taking into account a possible dropout of about 10% of 
the animals, 15 rats per group considered as sufficient for such a study. The expected loss of 
experimental rats believed because of developing undetectable tumors or other non-tumor-
related reasons. In the study, six rats were lost during the entire follow-up period, about 6.7% 
of all experimental animals (n = 90). 
In addition to the main tumor-suppressive function, Tp53 is involved in distinct essential cell-
signaling pathways that regulate the development, metabolism, and self-renewal capacity of the 
cells 142,143. Apparently, Tp53 is not a key gene of laboratory rat development since homozygous 
mutants are born. Moreover, the reproduction of rats of this line in the presented study was 
possible as at least six male zero mutants were able to produce F2 generation through mating 
with wild-type females (also see Table A1 and Table A2). Based on PCR amplification and 
sequence analysis of Tp53 DNAs, n = 35 experimental rats with heterozygous Tp53+/C273X 
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genotype were selected from F1 rat generation. Other experimental rats (n = 55) were not 
genotyped because these were the progeny of F1 wild-type female and homozygous male rats 
producing heterozygous progeny only. Thus, all rats used in the experiment had the same 
Tp53+/C273X background. Using homozygous males and wild-type females for breeding 
significantly reduces the total number of animals required for generating the Tp53+/C273X rats 
compared with heterozygous parents. The low number of ancestor rats limits the individual 
genetic heterogeneity in this experimental model and provides the possibility to compare 
radiation effects in genetically closely related animals. The balanced allocation of rats from 
each litter to different treatment groups done to balance possible false positive or negative 
influences of the ancestral background (Table M1 and Table A2). At the same time, a possibly 
balanced distribution by sex, as well as the age and weight of rats at the treatment, aspired 
(Table M2, Figure A1 – A2). 
Other p53-insufficient animal species would also have an interesting translational meaning for 
local dose-response research in order to determine the typical dose-response patterns that were 
conserved through the evolution between different species. Unlike Tp53C273X rats, in 
Transformation-related protein 53 (Trp53) knockout mice used in other studies, exon 2 – 6 has 
been replaced by the neo gene insert 144-146. Also in Tp53tm1[EGFP-pac] rats, exon 2 – 5 fragment 
of Tp53 gene is replaced by a reporter gene cassette 147. Although some differences in Tp53 
mutational signatures, there are general similarities, in terms of the type and the latency of 
sporadic tumors, between the other animal models mentioned above and rats used in this study. 
It is not clear, however, if the minor mutational differences between these models may influence 
the risk of radiation-induced carcinogenesis. Anyway, the comparison of the DRRs between 
these models could help to distinguish between radiation-specific and genetic-specific 
responses. However, it will be a long-lasting, very time-consuming, and expensive purpose.  
Taken together, all experimental rats, whether recruited to controls or radiation treatment 
groups, had a similar genetic background and living conditions. Therefore, a similar 
background risk was expected. Ultimately, it was well possible to study the relationships 
between simulated SCs and different irradiation techniques with the chosen, standardized 
tumor-prone animal model. 
Radiation planning and delivery 
No published data were available on irradiation of rats of the strain used in this experiment. 
Therefore, it was assumed that the planned total doses are theoretically similar to the total doses 
of 19 Gy and 36 Gy recommended by the German Hodgkin study group for the treatment of 
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mediastinal HL. This consonance between rats and humans remains limited translatable, 
because exact dose-response models for rats do not exist. 
A body size of a rat allows the radiation treatment carried out with a modern clinical LINAC 
equipped by a multi-leaf collimator system able to form the beam with a very small width at 
isocenter. It is less limited for rats than for smaller mice. However, there could be some 
limitations by means of precision in dose delivery to rats. 
An accuracy of irradiation was ensured by an advanced beam-forming collimator system. Given 
the width of the x-ray beam, the collimator system of the LINAC used in this experiment 
enabled to cover a 300 mm3 PTV with target doses while protecting the adjacent tissues, only 
a few millimeters distant from the PTV, from high doses. 
The precision in irradiation could be negatively impaired in rats due to the high-frequency heart- 
and lung activities. On the other hand, after CBCT-positioning using the MOSAIQ® platform, 
the differences between the particularly used radiation plan and the actual position of the PTV 
were usually decreased as maximally as possible. 
Both, the early and late effects of irradiation, can be influenced by the fractionation schedule 
148. The hypofractionated radiation regimen for every other day in the conducted experiment 
possibly helped to minimize expected negative physiological consequences of extensive 
anesthesia on successive days and to extend the total treatment time-window to five days.  
Regarding radiation protection of radiosensitive organs such as, for example, spine and lungs, 
which are commonly also protected in patients during RT. The irradiation plans, therefore, were 
made with an avoiding the delivery of high doses to these organs as maximally as possible. 
Taken together, all technical requirements were meet for creating radiation plans that are 
generally translatable in clinical VMAT and AP/PA plans. 
Sex-associated differences in tumor development 
In addition to organ-specific sensitivities to radiation in humans or even in rats, the induction 
of radiation-induced cancer can be influenced by the sex of an irradiated subject. An update of 
atomic bombing survivor’s data in 2007 showed that the rates of solid tumors per Gy was higher 
for women than man (58% vs. 35%) 78. In another study, cumulative SC incidence at 25 years 
after HL cure, was about 19% for females and 14% for males, whereas, excluding female breast 
cancer and prostate cancers, females have lower absolute risk for SC than males 22. 
The sex-specific difference in dose-response after thoracic irradiation of women and men, 
especially in HL treatment, is represented by increased female second breast cancer incidence, 
as described in the literature 28,88,149. Interestingly, although all four post-axillary mammary 
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glands in female rats were exposed to initial low doses during VMAT, no thoracic breast cancer 
could be observed in the low-dose volumes in female rats. Apparently, this rat model is also not 
notably prone to spontaneous breast cancer especially, since only three sporadic inguinal breast 
cancers were found in unirradiated volumes (Table R3). 
The weight at treatment and the growth increment were lower in female than in male rats, but 
the treatment weight was balanced between the groups and there was no notable difference 
observed in the growth pattern of unirradiated and irradiated rats (Figure A1). Somewhat more 
variability in the body sizes at treatment and during the growth was observed between male 
rats, while the weight of female rats was more invariant. Since female rats were irradiated with 
small radiation plans and males with large plans, the overall number of irradiated cells should 
be lower in females than males. This could have consequences for dose-response toward tumor 
incidence and latency. However, a comparison showed that neither the incidence nor the TTT 
was significantly different for radiation-associated tumors between female and male rats 
(Figure R12). 
By taking into the focus the entities of radiation-related tumors and to test a possible sex-
specificity of tumors, radiation-associated lymphoma and soft tissue sarcoma appeared to be 
coupled with sex, without any notable variability between the median TTTs. Therefore, the 
strong TTT shortening after 3×8 Gy treatment could not be influenced by sex-coupled incidence 
of lymphoma and soft tissue sarcoma. 
The increase in lymphoma incidence could also be related to increased received doses by larger 
thymus of male rats compared to females. This organ was exposed to high doses since located 
within the volume receiving more than 50% of each prescribed dose (3×5 Gy or 3×8 Gy). 
Age at treatment and attained age 
Childhood RT patients with mediastinal HL have an elevated risk of SC compared to adults 
18,19,28,88. An increase in risk of radiation-induced SC in children compared to adults has been 
supposed to be based on these three main reasons: first, the higher sensitivity of children to RT 
due to accelerated stem and progenitor cell proliferation rates, second, more critical response 
of the small body size of children to secondary scattered radiation, and third, genetic 
susceptibilities based on the frequent somatic mutations among pediatric cancer patients which 
are very rare 30,31,56,150. Therefore, younger rats could have a bit higher risk for radiation-induced 
tumor development than older congeners. However, this was not confirmed in the presented 
experiment, since the age in 3×8 Gy irradiated groups (gender-mixed) was median 37.5 days 
higher compared to other groups (106 [81 – 124] vs. 68.5 [58 – 108] days), with insignificant 
DISCUSSION 
78 
small variability between rats recruited to VMAT compared to AP/PA treatment groups (Figure 
A2a). According to the literature 151,152, laboratory rats are approximately 60 to 120 postnatal 
days in the young adult phase of their life. Therefore, all rats in the six experimental groups 
were young adults at the time of treatment and should have relatively similar background risks 
for tumor development. The main aim of the study, however, was to compare the response 
between two RT modalities and not between two different doses. 
For the compensation of the older age in 3×8 Gy treated rats a rough simulation of the data by 
addition of the median 37.5 days to the TTTs was performed. Although the extension of the 
TTTs by 37.5 days, the simulated TTT compared to AN/CBCT remained significantly 
decreased for the malignancies developed in the HDV after 3×8 Gy irradiation only (191 [139.5 
– 320.5] days, p = 0.0005), but no more for other tumors: median 264.5 [172.5 – 334.5] days 
for tumors in the NIRV, p = 0.23 and 261 [172.5 – 296.5] days for tumors within the 
LDV/BHDV combined, p = 0.22; Figure A2b). This indicates that a slightly older age should 
not be assumed to have a significant influence on the shortened latency of tumors after 3×8 Gy 
treatment of rats. Thus, there is clear evidence that high total doses could shorten the latency 
period for radiation-induced tumors, at least in cancer-prone rats. 
Potential risk modifiers 
The scenario of radiation-induced tumor development comprises several very complex 
successive events that are generated over time and interact with each other. In line with this, 
the risk of radiation-induced malignant late effects could be partly based on distinct early effects 
of the exposed normal tissues that display specific DRRs 118.  Indeed, it is currently believed 
that radiation carcinogenesis is the result of radiation-induced earlier and later effects on normal 
tissues, which can include multiple systemic reactions, such as premature aging, inflammation, 
genetic instability, vascular and immunity disorders, etc 153-157. 
In this context, an increased risk for the development of radiation-associated breast cancer in a 
translational mice model has been associated with locally established tumor micro-environment 
135-137,158,159.  
Anyway, the micro-environment of tumors and the immune response of exposed tissues to 
different radiation doses will be a substantial topic for future studies as it is also described in 
different studies compiled in a paper by Deloch et al 160. 
Overall, translational RT research is faced with the challenge of further expanding 
interdisciplinary and cross-thematic areas in order to determine in-depth knowledge of possible 




The development of SC related to radiation treatment of cancers has been over a long time 
associated with received low doses based on the dose-response data derived from ABSs. Recent 
technological advances in RT allow treatment beams to be precisely tailored to different tumor 
geometries, achieving high conformality and avoiding high doses to normal tissue. A 
consequence of such highly conformal IMRT technology (such as VMAT) is that larger 
volumes of healthy tissue are exposed to low and moderate radiation doses. However, a widely 
accepted dogma in radiation oncology postulates that IMRT increases the risk of SC compared 
to conventional simple 3D-CRT techniques, such as AP/PA irradiation.  For this reason, IMRT 
is avoided in patients, especially young patients, expected to survive long-term, and the 
withholding of the benefits of dose-sparing IMRT from patients, accepting thereby high dose-
related risks for heart, breast, and other critical organs. 
Challenging the assumption of increased late toxicity of IMRT by performing the first-of-its-
kind experiment with cancer-susceptible rats irradiated with either VMAT or AP/PA, resulted 
in a predominant appearance of radiation-induced tumors in the regions receiving high doses 
unlike to low doses. The results obtained do not support the hypothesis that a larger low-dose 
volume during IMRT can increase the risk of SC, but rather suggest a greatly increased risk of 
SC per unit volume at higher doses. Most importantly, no increased tumor rates or decreased 
latency after VMAT vs. AP/PA were observed. Furthermore, the results for the first time 
demonstrated a significantly decreased latency time to tumors developing in the volume 
exposed to very high doses (24 Gy). Obtained results corroborate recent evidence from 
localized RT assuming a linear increase in a DRR up to 4 – 8 Gy received doses and does not 
support classical radiation carcinogenesis models assuming a saturation or even a decrease 
above this dose range, with no further increase at higher doses. 
Because a reduction of doses and irradiated volumes in the treatment of childhood cancer has 
led to fewer SC and serious complications within the healthy tissue after RT, the reduced high-
dose volume in modern conformal IMRT might decrease the risk of SC and possibly balance 
the hypothetical increase in risk associated with larger low-dose volumes. 
Future translation studies looking at a more detailed characterization of dose-response 
relationships and the underlying mechanisms of radiation carcinogenesis after RT in living 
animals should be conducted to support the clinical use of modern IMRT techniques as safer 
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Sequence information A1 
Rat and human DNA-binding Tp53 fragments. (a) An exemplary sequence of endogenous rat Tp53 
DNA containing exon 6 with a C273X nonsense mutation TGT/TGA (asterisk, stop codon) at position 
817. (b) Representative human TP53 exon 8 containing sequence, showing deep similarity to the 
orthologous DNA and amino acid sequences of the rat. Evolutionary conserved (identical) amino acid 
sequences are colored green and red are the alterations. The triplets coding the rat C273 (817 – 819), 
and its orthologous human C275 (TGT 824 – 826), are underscored. The two major mutational sites in 






257  D   S   S   G   N   L   L   G   R   D   S   F   E   V   R   V   272     
769 GAC TCC AGT GGG AAT CTT CTG GGA CGG GAC AGC TTT GAG GTT CGT GTT  816 
 
273  *   A   C   P   G   R   D   R   R   T   E   E   E   N   F   R   288 
817 TGA GCC TGT CCT GGG AGA GAC CGT CGG ACA GAG GAA GAA AAT TTC CGC  864 
 
289  K   K   E   E   H   C   P   E   L   P   P   G   S   A   K   R   304  







257  L   E   D   S   S   G   N   L   L   G   R   N   S   F   E   V   272     
769 CTG GAA GAC TCC AGT GGT AAT CTA CTG GGA CGG AAC AGC TTT GAG GTG  816     
 
273  H   V   C   A   C   P   G   R   D   R   R   T   E   E   E   N   288     
817 CAT GTT TGT GCC TGT CCT GGG AGA GAC CGG CGC ACA GAG GAA GAG AAT  864     
 
289  L   R   K   K   G   E   P   H   H   E   L   P   P   G   S   T   304     














Sequence information A2 
Representative 4523 bases long Tp53 PCR product (5´- 3´). The capitals represent exons and bolded 
























































Rat data 1. (A) Rat identity and sex (female/male), (B) parental Tp53-background of Tp53X/C273 
individuals of the L1 - L11 litters of F1 and F2 generations derived from three female Aa, Bb, Cc and 
two male Dd and Ee allele pairs (the capital letters represent intact Tp53 alleles and the regular letters 
mean the Tp53+/C273X knock out variants); (C) weight at treatment(± 5 g); (D) attained weight (± 5 g); 
(E) weight increment (± 5 g); (F) growth rate (gram per follow up day); (G)  the age at first follow-up 
CT (days); (H) the attained age (days); and (I) the age at treatment (days).  
 
 
A B C D E F G H I 
91m F1, L1; f [A or a] × m [D or d] 250 420 170 0,78 − 287 69 
65m F1, L1; f [A or a] × m [D or d] 230 425 195 0,66 257 362 66 
5m F1, L2; f [C or c] × m [B or b] 240 435 195 0,9 − − 64 
51''m F2, L9; f [B or E] × m [a or d] 235 465 230 0,78 216 380 58 
46''m F2, L7; f [A or D] × m [b or e] 275 515 240 0,81 219 − 59 
15'f F1, L1; f [A or a] × m [D or d] 185 330 145 0,38 312 451 71 
28''f F2, L7; f [A or D] × m [b or e] 170 330 160 0,55 282 357 68 
26''f F2, L7; f [A or D] × m [b or e] 180 245 65 0,34 − 259 68 
85f F1, L3; f [B or b] × m [E or e] 180 245 65 0,3 268 300 82 
88f F1, L3; f [B or b] × m [E or e] 185 260 75 0,24 271 402 85 
14'f F1, L1; f [A or a] × m [D or d] 185 200 15 0,11 − − 71 
50''m F2, L9; f [B or E] × m [a or d] 245 400 155 0,61 216 291 58 
41''m F2, L4; f [C or B] × m [a or d] 225 400 175 0,68 216 310 61 
43''m F2, L4; f [C or B] × m [a or d] 285 485 200 1,3 − 575 61 
95f F1, L1; f [A or a] × m [D or d] 190 300 110 0,27 347 478 70 
33''f F2, L4; f [C or B] × m [a or d] 155 250 95 0,25 282 449 68 
10f F1, L3; f [B or b] × m [E or e] 175 276 101 0,44 − 301 70 
43´´´m F2, L10; f [A or D] × m [b or e] 220 310 90 0,45 243 297 95 
29´´m F2, L8; f [A or D] × m [b or e] 290 405 115 1,1 − − 93 
64''f F2, L6; f [B or C] × m [a or d] 220 250 30 0,17 263 282 107 
86''f F2, L10; f [A or D] × m [b or e] 200 225 25 0,17 − 246 116 
22´´m F2, L6; f [B or C] × m [a or d] 280 345 65 0,64 − 202 100 
27´´´m F2, L5; f [C or B] × m [a or d] 260 335 75 0,56 215 − 103 
93''m F2, L11; f [A or D] × m [b or e] 265 345 80 0,59 − 223 88 
99''m F2, L11; f [A or D] × m [b or e] 250 330 80 0,59 − 223 88 
24´´m F2, L6; f [B or C] × m [a or d] 330 440 110 0,55 235 300 100 
82''f F2, L10; f [A or D] × m [b or e] 205 240 35 0,19 246 305 116 
58''f F2, L6; f [B or C] × m [a or d] 190 220 30 0,22 − 241 107 
52´´f F2, L6; f [B or C] × m [a or d] 205 285 80 0,28 263 390 107 
60''f F2, L6; f [B or C] × m [a or d] 205 245 40 0,24 − 263 107 
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81´´f F2, L11; f [A or D] × m [b or e] 180 215 35 0,19 239 291 109 
44´´f F2, L11; f [A or D] × m [b or e] 215 265 50 0,20 256 354 107 
79f F2, L11; f [A or D] × m [b or e] 215 300 85 0,33 − − 107 
38''m F2, L4; f [C or B] × m [a or d] 225 395 170 0,63 219 330 61 
48''m F2, L7; f [A or D] × m [b or e] 280 440 160 1,32 − 176 61 
20'm F1, L1; f [A or a] × m [D or d] 245 415 170 0,48 317 − 65 
71f  F1, L1; f [A or a] × m [D or d] 165 270 105 0,34 256 383 72 
9f F1, L3; f [B or b] × m [E or e] 180 325 145 0,43 304 407 70 
39''f F2, L4; f [C or B] × m [a or d] 225 380 155 0,63 216 − 61 
16'm F1, L1; f [A or a] × m [D or d] 250 435 185 0,63 317 358 65 
63m F1, L1; f [A or a] × m [D or d] 280 490 210 0,70 257 364 66 
69f F1, L1; f [A or a] × m [D or d] 160 265 105 0,29 256 431 72 
23''f F2, L7; f [A or D] × m [b or e] 175 245 70 0,45 − − 68 
18f F1, L3; f [B or b] × m [E or e] 160 235 75 0,26 − 365 77 
89f F1, L3; f [B or b] × m [E or e] 210 290 80 0,26 271 388 85 
47´´f F2, L11; f [A or D] × m [b or e] 225 280 55 0,29 255 297 106 
37´´m F2, L8; f [A or D] × m [b or e] 330 470 140 0,48 262 390 100 
98''m F2, L11; f [A or D] × m [b or e] 240 385 145 0,71 236 293 88 
31´´m F2, L8; f [A or D] × m [b or e] 335 480 145 0,53 262 368 93 
42´´´m F2, L10; f [A or D] × m [b or e] 285 450 165 0,58 − 365 81 
6´´f F2, L5; f [C or B] × m [a or d] 220 270 50 0,20 252 373 124 
54''f F2, L6; f [B or C] × m [a or d] 200 265 65 0,26 263 − 114 
90''f F2, L10; f [A or D] × m [b or e] 185 220 35 0,19 246 305 116 
56''f F2, L6; f [B or C] × m [a or d] 215 275 60 0,31 263 298 107 
33´´´m F2, L8; f [A or D] × m [b or e] 280 435 155 0,52 − 390 93 
32´´m F2, L8; f [A or D] × m [b or e] 290 390 100 0,53 − 282 93 
36´´m F2, L10; f [A or D] × m [b or e] 330 425 95 0,70 − 216 81 
49''m F2, L7; f [A or D] × m [b or e] 295 480 185 0,69 − − 68 
75m F1, L3; f [B or b] × m [E or e] 275 490 215 0,5 249 504 73 
42''m F2, L4; f [C or B] × m [a or d] 285 500 215 0,73 − 359 68 
21'm F1, L1; f [A or a] × m [D or d] 275 485 210 0,83 397 317 65 
3´ m F1, L2; f [C or c] × m [B or b] 240 425 185 0,56 − 392 64 
59m F1, L1; f [A or a] × m [D or d] 265 455 190 0,67 257 − 66 
19f F1, L3; f [B or b] × m [E or e] 185 235 50 0,39 − − 77 
34''f F2, L4; f [C or B] × m [a or d] 165 235 70 0,23 282 − 68 
87f F1, L3; f [B or b] × m [E or e] 190 275 85 0,32 271 352 85 
96f F1, L1; f [A or a] × m [D or d] 200 280 80 0,23 310 441 96 
92f F1, L1; f [A or a] × m [D or d] 195 285 90 0,46 − 268 82 
12'f F1, L1; f [A or a] × m [D or d] 180 270 90 0,31 312 366 71 
7f F1, L3; f [B or b] × m [E or e] 165 245 80 0,23 304 304 70 
30''f F2, L4; f [C or B] × m [a or d] 155 255 100 0,28 282 − 68 
11m F1, L3; f [B or b] × m [E or e] 175 335 160 0,49 326 392 63 
35''m F2, L4; f [C or B] × m [a or d] 265 450 185 0,62 219 408 108 
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57m F1, L1; f [A or a] × m [D or d] 250 410 160 0,54 257 362 66 
13m F1, L3; f [B or b] × m [E or e] 280 490 210 0,6 316 415 64 
62m F1, L1; f [A or a] × m [D or d] 270 410 140 0,74 − 262 73 
27''m F2, L9; f [B or E] × m [a or d] 220 450 230 0,95 262 283 85 
40''m F2, L4; f [C or B] × m [a or d] 300 450 150 0,73 285 294 108 
8f F1, L3; f [B or b] × m [E or e] 185 260 75 0,24 304 379 64 
2''f F2, L9; f [B or E] × m [a or d] 150 235 85 0,59 − − 85 
4''f F2, L9; f [B or E] × m [a or d] 145 285 140 0,36 262 472 85 
94f F1, L1; f [A or a] × m [D or d] 165 300 135 0,32 313 499 82 
1''f F2, L9; f [B or E] × m [a or d] 155 290 135 0,59 262 − 85 
20f F1, L3; f [B or b] × m [E or e] 190 320 130 0,32 − 483 76 
Rats killed due to non-tumor-related causes:  
53''f F2, L6; f [B or C] × m [a or d] 210 245 35 0,2 263 − 107 
45´´f F2, L11; f [A or D] × m [b or e] 210 255 45 0,27 256 − 107 
97f F1, L1; f [A or a] × m [D or d] 180 215 35 0,38 − − 82 
21''f F2, L7; f [A or D] × m [b or e] 185 290 105 0,45 − − 68 
19'm F1, L1; f [A or a] × m [D or d] 263 435 172 0,56 − − 65 
83f F1, L3; f [B or b] × m [E or e] 190 290 100 0,64 240 − 85 
 
Abbreviations: rat identity and sex (e. g. #1´´f, number 1´´ female), m, male; F1 and F2 filial generation 





























Rat breeding scheme. Generation of heterozygous Tp53+/C273X experimental rats (black) rats from 
heterozygous only or homozygous (Tp53C273X/C273X) and wild-type (Tp53wt) parents. Original Tp53 
























Abbreviations: F1 and F2, Filial generation 1 and 2; L1-L11, litter 1-11; Tp53, Tumor protein 53; Gy, 
Gray; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/ posterior-anterior; AN, 
anesthesia only; CBCT, cone-beam CT only.  











#19´♂ AN #3´ CBCT #8♀ AN
#57♂ AN #5´ 3×5 Gy VMAT #11♂ AN
#94♀ AN #13♂ AN
#62♂ AN #20♀ AN
#12´♀ CBCT #83♀ AN
#59♂ CBCT #7♀ CBCT
#21´ CBCT #19♀ CBCT
#92♀ CBCT #75♂ CBCT
#96♀ CBCT #87♀ CBCT
#15´♀ 3×5 Gy VMAT #9♀ 3×5 Gy VMAT
#20´♂ 3×5 Gy VMAT #88♀ 3×5 Gy VMAT
#65♂ 3×5 Gy VMAT #85♀ 3×5 Gy VMAT
#71♀ 3×5 Gy VMAT #10♀ 3×5 Gy APPA
#91♂ 3×5 Gy VMAT #18♀ 3×5 Gy APPA
#14´♀ 3×5 Gy APPA #89♀ 3×5 Gy APPA
#16´♂ 3×5 Gy APPA
#63♂ 3×5 Gy APPA
#69♀ 3×5 Gy APPA
#95♀ 3×5 Gy APPA










#39´´♂ 3×5 Gy APPA
#38´´♂ 3×5 Gy VMAT
#33´´♀ 3×5 Gy AP/PA
#41´´♂ 3×5 Gy APPA





#6´´♀: 3×8 Gy VMAT





#53´´♀ 3×8 Gy VMAT
#54´´♀ 3×8 Gy VMAT
#56´´♀ 3×8 Gy VMAT
#64´´♀ 3×8 Gy VMAT
#22´´♂ 3×8 Gy APPA
#24´´♂ 3×8 Gy APPA
#52´´♀ 3×8 Gy APPA
#58´´♀ 3×8 Gy APPA







#26´´♀ 3×5 Gy VMAT
#28´´♀ 3×5 Gy VMAT
#46´´♂ 3×5 Gy VMAT
#48´´♂ 3×5 Gy VMAT
#23´´♀ 3×5 Gy APPA
#79♂Tp53
C273X/C273X
#29´´♂ 3×8 Gy VMAT
#31´´♂ 3×8 Gy VMAT
#37´´♂ 3×8 Gy VMAT
#32´´♂ 3×8 Gy APPA









#51´´♂ 3×5 Gy VMAT





#43´´´♂ 3×8 Gy VMAT
#86´´♀ 3×8 Gy VMAT
#90´´♀ 3×8 Gy VMAT
#42´´´♂ 3×8 Gy VMAT
#36´´♂ 3×8 Gy APPA
#82´´♀ 3×8 Gy APPA
#70(90)♀Tp53
wt
#45´´♀ 3×8 Gy VMAT
#47´´♀ 3×8 Gy VMAT
#98´´♂ 3×8 Gy VMAT
#44´´♀ 3×8 Gy APPA
#79´´♀ 3×8 Gy APPA
#81´´♀ 3×8 Gy APPA
#93´´♂ 3×8 Gy APPA























Rat data 2. (A) Rat identity and sex (female/male). (B) Radiation treatment plan size based on 160 g 
(small) and 250 g (large) rat planning CTs. (C) Used dose delivering technique (VMAT or AP/PA). (D) 
Fraction number and the fraction dose in Gy (Gray). (E) The volume (cm3) affected by index tumors: 
high dose volume (HDV), bordering HDV (BHDV), low dose volume (LDV), and non-irradiated 
volume (NIRV); (F) the size (cm3) of volumes in which tumors were found. (G) Dose to volume 
relationships (DVRs) in percent of minimal received doses calculated using Monaco®; (H) estimated 
received total doses in Gy, and (I) time to tumor (TTT) from the first treatment fraction (days). 
 
 
A B C D E F G H I 
91m Large VMAT 3×5 Gy HDV 0.782 >90% >13.5 Gy 218 
65m Large VMAT 3×5 Gy HDV 0.782 >90% >13.5 Gy 296 
5m Large VMAT 3×5 Gy HDV 0.782 >90% >13.5 Gy 217 
51''m Large VMAT 3×5 Gy BHDV 3.884 50-90% 7.5-13.5 Gy 296 
46''m Large VMAT 3×5 Gy HDV 0.782 >90% >13.5 Gy 298 
15'f Small VMAT 3×5 Gy HDV 0.66 >90% >13.5 Gy 380 
28''f Small VMAT 3×5 Gy HDV 0.66 >90% >13.5 Gy 289 
26''f Small VMAT 3×5 Gy HDV 0.66 >90% >13.5 Gy 191 
85f Small VMAT 3×5 Gy LDV 12.394 5-50% 0.75-7.5 Gy 218 
88f Small VMAT 3×5 Gy LDV 12.394 5-50% 0.75-7.5 Gy 317 
14'f Small AP/PA 3×5 Gy HDV 1.265 >90% >13.5 Gy 137 
50''m Large AP/PA 3×5 Gy HDV 2.465 >90% >13.5 Gy 256 
41''m Large AP/PA 3×5 Gy HDV 2.465 >90% >13.5 Gy 258 
43''m Large AP/PA 3×5 Gy HDV 2.465 >90% >13.5 Gy 154 
95f Small AP/PA 3×5 Gy HDV  1.265 >90% >13.5 Gy 408 
33''f Small AP/PA 3×5 Gy BHDV 3.394 50-90% 7.5-13.5 Gy 381 
10f Small AP/PA 3×5 Gy LDV 7.369 5-50% 0.75-7.5 Gy 231 
43´´´m Large VMAT 3×8 Gy HDV 0.782 >90% >21.6 Gy 202 
29´´m Large VMAT 3×8 Gy HDV 0.782 >90% >21.6 Gy 105 
64''f Large VMAT 3×8 Gy HDV 0.782 >90% >21.6 Gy 175 
86''f Small VMAT 3×8 Gy HDV 0.66 >90% >21.6 Gy 143 
22´´m Large AP/PA 3×8 Gy HDV 2.465 >90% >21.6 Gy 102 
27´´´m Large AP/PA 3×8 Gy HDV 2.465 >90% >21.6 Gy 133 
93''m Large AP/PA 3×8 Gy HDV 2.465 >90% >21.6 Gy 135 
99''m Large AP/PA 3×8 Gy LDV 12.029 5-50% 1.2-12.0 Gy 135 
24´´m Large AP/PA 3×8 Gy LDV 12.029 5-50% 1.2-12.0 Gy 200 
82''f Small AP/PA 3×8 Gy HDV 1.265 >90% >21.6 Gy 189 
58''f Small AP/PA 3×8 Gy HDV 1.265 >90% >21.6 Gy 134 
52´´f Small AP/PA 3×8 Gy HDV 1.265 >90% >21.6 Gy 283 
60''f Small AP/PA 3×8 Gy HDV 1.265 >90% >21.6 Gy 164 
81´´f Small AP/PA 3×8 Gy BHDV 3.394 50-90% 12-21.6 Gy 182 
44´´f Small AP/PA 3×8 Gy LDV 7.369 5-50% 1.2-12.0 Gy 247 
APPENDIX 
97 
79f Small AP/PA 3×8 Gy LDV 7.369 5-50% 1.2-12.0 Gy 259 
38''m Large VMAT 3×5 Gy NIRV 195.55 <5% <0.75 Gy 269 
48''m Large VMAT 3×5 Gy NIRV 195.55 <5% <0.75 Gy 121 
20'm Large VMAT 3×5 Gy NIRV 195.55 <5% <0.75 Gy 353 
71f  Small VMAT 3×5 Gy NIRV 127.59 <5% <0.75 Gy 311 
9f Small VMAT 3×5 Gy NIRV 127.59 <5% <0.75 Gy 337 
39''f Large AP/PA 3×5 Gy NIRV 203.13 <5% <0.75 Gy 247 
16'm Large AP/PA 3×5 Gy NIRV 203.13 <5% <0.75 Gy 293 
63m Large AP/PA 3×5 Gy NIRV 203.13 <5% <0.75 Gy 298 
69f Small AP/PA 3×5 Gy NIRV 131.55 <5% <0.75 Gy 359 
23''f Small AP/PA 3×5 Gy NIRV 131.55 <5% <0.75 Gy 154 
18f Small AP/PA 3×5 Gy NIRV 131.55 <5% <0.75 Gy 288 
89f Small AP/PA 3×5 Gy NIRV 131.55 <5% <0.75 Gy 303 
47´´f Large VMAT 3×8 Gy NIRV 195.55 <5% <1.2 Gy 191 
37´´m Large VMAT 3×8 Gy NIRV 195.55 <5% <1.2 Gy 290 
98''m Large VMAT 3×8 Gy NIRV 195.55 <5% <1.2 Gy 205 
31´´m Large VMAT 3×8 Gy NIRV 195.55 <5% <1.2 Gy 275 
42´´´m Large VMAT 3×8 Gy NIRV 195.55 <5% <1.2 Gy 284 
6´´f Large VMAT 3×8 Gy NIRV 195.55 <5% <1.2 Gy 249 
54''f Small VMAT 3×8 Gy NIRV 127.59 <5% <1.2 Gy 252 
90''f Small VMAT 3×8 Gy NIRV 127.59 <5% <1.2 Gy 189 
56''f Small VMAT 3×8 Gy NIRV 127.59 <5% <1.2 Gy 191 
33´´´m Large AP/PA 3×8 Gy NIRV 203.13 <5% <1.2 Gy 297 
32´´m Large AP/PA 3×8 Gy NIRV 203.13 <5% <1.2 Gy 189 
36´´m Large AP/PA 3×8 Gy NIRV 203.13 <5% <1.2 Gy 135 
49''m − CBCT 3×0.04 Gy − − − <0.04 Gy 268 
75m − CBCT 3×0.04 Gy − − − <0.04 Gy 431 
42''m − CBCT 3×0.04 Gy − − − <0.04 Gy 294 
21'm − CBCT 3×0.04 Gy − − − <0.04 Gy 252 
3´ m − CBCT 3×0.04 Gy − − − <0.04 Gy 328 
59m − CBCT 3×0.04 Gy − − − <0.04 Gy 282 
19f − CBCT 3×0.04 Gy − − − <0.04 Gy 128 
34''f − CBCT 3×0.04 Gy − − − <0.04 Gy 303 
87f − CBCT 3×0.04 Gy − − − <0.04 Gy 267 
96f − CBCT 3×0.04 Gy − − − <0.04 Gy 345 
92f − CBCT 3×0.04 Gy − − − <0.04 Gy 196 
12'f − CBCT 3×0.04 Gy − − − <0.04 Gy 295 
7f − CBCT 3×0.04 Gy − − − <0.04 Gy 352 
30''f − CBCT 3×0.04 Gy − − − <0.04 Gy 357 
11m − AN 0 − − − 0 Gy 329 
35''m − AN 0 − − − 0 Gy 300 
57m − AN 0 − − − 0 Gy 296 
13m − AN 0 − − − 0 Gy 351 
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62m − AN 0 − − − 0 Gy 189 
27''m − AN 0 − − − 0 Gy 242 
40''m − AN 0 − − − 0 Gy 205 
8f − AN 0 − − − 0 Gy 315 
2''f − AN 0 − − − 0 Gy 143 
4''f − AN 0 − − − 0 Gy 387 
94f − AN 0 − − − 0 Gy 417 
1''f − AN 0 − − − 0 Gy 228 
20f − AN 0 − − − 0 Gy 407 
53''f Small VMAT 3×8 Gy Sacrificed due to non-tumor causes 179 
45´´f Small VMAT 3×8 Gy Sacrificed due to non-tumor causes 164 
97f Small AP/PA 3×5 Gy Sacrificed due to non-tumor causes 91 
21''f − CBCT 3×0.04 Gy Sacrificed due to non-tumor causes 232 
19'm − AN 0 Sacrificed due to non-tumor causes 308 
83f − AN 0 Sacrificed due to non-tumor causes 156 
 
Abbreviations: rat identity and sex (e. g. #1´´f, number 1´´ female), m, male; VMAT, volumetric-
modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior irradiation; CBCT, cone-beam 
computed tomography only controls; AN, anesthesia only controls; Gy, Gray; HDV, high-dose volume; 
BHDV, bordering high-dose volume; LDV, low-dose volume; NIRV, non-irradiated volume; TTT, time 






















Frequency distribution of tumors in different dose-volumes. The frequency distribution of tumors in 
different dose-volumes. The incident numbers and total volumes of affected NIRVs, LDVs, BHDVs, 
and HDVs were summed (based on Monaco Statistics®) and then, ordered by estimated dose levels, and 
grouped either by prescribed doses (3×5 Gy and 3×8 Gy) or by used irradiation technique (VMAT and 
AP/PA). The frequency distribution was calculated by dividing of incidence numbers by the summed 
dose-volumes. An estimate of the sizes of each particular volume, in which an index tumor was 
developed, bases on the Monaco statistics data and takes into account the particularly prescribed doses, 




Abbreviations: NIRV, non-irradiated volume; LDV, low-dose volume; BHDV, bordering high-dose 





Dose Volume NIRV LDV BHDV HDV 
 
Estimated received dose after 3×5 Gy <0.75 Gy 0.75-7.5 Gy 7.5-13.5 Gy 13.5-15 Gy 
Number of tumors after 3×5 Gy 12 3 2 12 
Total volume in cm3 after 3×5 Gy 1977.42 32.157 10.672 17.65 
Distribution (n per cm3) after 3×5 Gy 0.006 0.093 0.187 0.68 
 
Estimated received dose after 3×8 Gy <1.12 Gy 1.12-12 Gy 12-21.6 Gy 21.6-24 Gy 
Number of events after 3×8 Gy 12 4 1 11 
Total volume in cm3 after 3×8 Gy   2165.46 38.796 6.788 16.016 
Distribution (n per cm3) after 3×8 Gy 0.0054 0.1 0.147 0.67 
 
Number of events after VMAT 14 2 1 11 
Total volume in cm3 after VMAT 2397.9 24.788 3.884 10.178 
Distribution (n per cm3) after VMAT 0.005 0.08 0.257 1.08 
 
Number of events after AP/PA 10 5 2 12 
Total volume in cm3 after AP/PA 1744.98 46.165 13.576 23.29 




The organ DVRs for 3×5 Gy. Shown are the dose and volume parameter of the small and large 
irradiation plans for VMAT and AP/PA irradiation (Monaco® statistics). 
 
Structures at risk 
Irradiation 
technique 
Volume (cm3) Dmin (Gy) Dmax (Gy) 
Large Small Large Small Large Small 
PTV VMAT 0.296 0.296 13.80 13.28 15.99 16.03 
AP/PA 0.296 0.296 12.47 13.02 15.95 15.65 
Spine 
VMAT 4.14 2.4 0.003 0.007 15.1 14.8 
AP/PA 4.14 2.4 0.09 0.08 16.09 15.06 
Heart 
VMAT 1.45 1.55 0.72 0.7 14.9 16.03 
AP/PA 1.45 1.55 0.41 0.61 16.2 15.60 
Thymus 
VMAT 0.39 0.46 0.06 0.04 2.28 11.42 
AP/PA 0.39 0.46 0.23 0.18 6.04 9.58 
Sternum 
VMAT 0.74 0.54 0.02 0.02 3.27 5.58 
AP/PA 0.74 0.54 0.17 0.09 15.33 13.9 
Lung right 
VMAT 3.33 1.35 0.24 0.26 15.29 15.53 
AP/PA 3.33 1.35 0.22 0.2 15.85 15.32 
Lung left 
VMAT 2.81 0.94 0.42 0.28 15.78 15.44 
AP/PA 2.81 0.94 0.24 0.23 15.77 15.65 
Chest wall right 
VMAT 6.58 5.33 0.015 0.014 10.12 11.9 
AP/PA 6.58 5.33 0.041 0.023 15.6 14.15 
Chest wall left 
VMAT 6.51 5.21 0.015 0.014 8.57 11.90 
AP/PA 6.51 5.21 0.04 0.03 15.16 14.80 
Back muscles right 
VMAT 3.62 2.12 0.02 0.008 6.6 4.07 
AP/PA 3.62 2.12 0.014 0.015 14.62 13.32 
Back muscles left 
VMAT 3.92 2.36 0.03 0.008 6.19 5.17 
AP/PA 3.92 2.36 0.02 0.02 15.12 13.57 
Axilla (armpit) right 
VMAT 2.14 1.75 0.05 0.02 5.45 6.25 
AP/PA 2.14 1.75 0.09 0.013 2.35 0.63 
Axilla (armpit) left 
VMAT 2.14 1.77 0.04 0.005 4.85 5.45 
AP/PA 2.14 1.77 0.07 0.0 0.51 0.68 
Kidney right 
VMAT 1.39 1.21 0.014 0.007 0.14 0.06 
AP/PA 1.39 1.21 0.012 0.0 0.20 0.09 
Kidney left 
VMAT 1.4 1.21 0.012 0.011 0.11 0.07 
AP/PA 1.4 1.21 0.01 0.0 0.21 0.24 
Liver 
VMAT 12.59 7.82 0.01 0.06 11.92 12.21 
AP/PA 12.59 7.82 0.02 0.23 14.21 15.65 
Intestine 
VMAT 1.46 0.68 0.002 0.01 0.04 0.034 
AP/PA 1.46 0.68 0.0 0.07 0.16 0.015 
Stomach  
VMAT 6.8 4.9 0.014 0.05 0.46 0.69 
AP/PA 6.8 4.9 0.02 0.06 0.76 1.5 
 
Abbreviations: Dmin and Dmax, minimal and maximal doses; NIRV, non-irradiated volume; PTV, 
planning target volume; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-




The DICOM data list of the rat CT. The original file IDs are listed. SOMATOM Force data were 
saved on the server of the Department of Clinical Radiology and Nuclear Medicine, Medical Faculty 
Mannheim of Heidelberg University) and on WD Server (4 TB) #WCC4E2NJO3Y6 (WD® NL B. V. 
Hoofddorp, the Netherlands) under project number G184-14 (Department of Radiation Oncology of the 
University Medical Center Mannheim of Heidelberg University).  
 
 
#91m_VMAT15_1FCTn_17.02.2016  - 
#65m_VMAT15_1FCTn_23.12.2015,  #65m_VMAT15_2FCTc_06.04.2016 
#51m_VMAT15_1FCTn_08.01.2016,  #51m_VMAT15_FCTc_fin_20.06.2016 
#46´´m_VMAT15_1FCTn_08.01.2016  - 
#15´L0R2f_VMAT15_1FCTn_17.12.2015, #15'L0R2.f_VMAT15 fin.-FCTc_04.05.2016 
#28´´f_VMAT15_1FCTn_11.03.2016  #28´´f_VMAT15_FCTc_fin_25.5.16 
#26´´f_VMAT15_1FCTn_17.02.2016  - 
#85f_VMAT15_2FCTn_29.01.2016  #85f_VMAT15_1FCTn_01.03.2016 
#88f_VMAT15_1FCTn_29.01.2016  #88´´f_VMAT15_FCTc-fin_08.06.2016 
#50´´m_APPA15_1FCTn_08.01.2016  #50´´m_APPA15_2FCTn_23.03.2016 
#41´´m_APPA15_1FCTn_05.01.2016  #41´´m_APPA15c_8.4.2016 
#43´´m_APPA15_finFCTn_29.12.2016  - 
#43´´´m_VMAT24_1FCT_19.4.2016  #43´´´m_VMAT24_2-finFCT_12.6.16 
#95f_APPA15_1FCTn_29.01.2016  #95f_APPA15-160 fin. fCTc2´_08.06.16 
#33´´f_APPA15_1FCTn_11.03.2016  #33´´m_APPA24_2FCTn.19.8.16  
      #33´´f_APPA15_finFCTc_25.8.16 
#10f_APPA15_2XFCT_14.12.15  - 
#64f_VMAT24_1FCTn_20.4.2016  #64f_VMAT24_2FCTc_fin_09.05.2016 
#86´´f_VMAT24_22.4.2016   - 
#22´´m_APPA24_1FCTn_19.02.2016  - 
#93´´m_APPA24_1FCTc_06.04.2016  #99´´m_APPA24_1FCTn_06.04.2016 
#24''m_APPA24_1FCTn_23.03.2016  #24´´m_APPA24_2finFCTc_27.05.2016 
#82´´f_APPA24_22.4.2016   #82´´f_APPA24_finFCTc_20.06.2016 
#58´´f_APPA24_1finFCTc_29.03.2016  - 
#52´´f_APPA24_20.4.2016   #52f_APPA24_finFCTc_25.08.2016_2Recons 
#60´´f_APPA24_1FCTn_20.4.2016  - 
#81´´f_APPA24_1FCTn_22.4.2016  #81´´f_APPA24_finFCT_13.06.2016 
#44´´f_APPA24_1FCTn_13.4.2016  #44´´f_APPA24_2finFCTc_20.07.2016 
#38´´m_VMAT15_1FCTn_08.01.2016  #38m_VMAT15_2-2XfinFCTc_28.4.2016 
#48m_VMAT15_1FCTn_26.11.2015  - 
#20´L0R3m_VMAT15_1FCTn_22.12.2015 - 
#71(91)f_VMAT15_1FCTn_23.12.2015 #71(91)f_APPA15_28.4.2016 
#9f_VMAT15_1FCTn_17.12.2015  #9f_VMAT15_2FCTc_fin_29.03.2016 
#39´´m_APPA15_1FCTn_05.01.2016  - 
#16´L2R1m (19)-APPA15_22.12.15  #16´L2R1m_APPA15_1FCTn_02.02.2016 
#63m_APPA15_1FCTn_23.12.2015  #63m_APPA15_2FCTc_08.04.2016 
#69f_APPA15_1FCTn_23.12.2015  #69f_APPA15_FCTc_15.06.2016 
#18f_APPA15_1FCTn_16.02.2016  - 
#89´´f_APPA15_1FCTn_29.01.2016  #89´´f_APPA15_2FCTc_25.05.2016 





#98´´m_VMAT24_19.04.2016   #98m_VMAT24_fin-2XFCTc_15.07.2016 
#31´´m_VMAT24_19.4.2016   #31´´m_VMAT24_FCTc2-fin_03.08.2016 
#42´´´m_VMAT24_2 X fin. FCTn_19.8.16 - 
#6´´f_VMAT15-1FCTn_24_20.04.16  #6´´f_VMAT24_19.8.16_2Recons 
#54´´f_VMAT24_20.04.2016   - 
#90´´f_VMAT24_22.04.2016   #90f_VMAT24_FCTc-fin_20.06.2016 
#56´´f_VMAT24_1FCTn_20.4.2016  #56´´f_VMAT24_2FCTc_25.05.2016 
#33´´´m APPA24_fCTc.fin. 25.8.16  - 
#32´´m_APPA24_FCTc_09.05.16  - 
#36''m_APPA24_1FCTn_23.03.2016  - 
#75m_CBCT_1FCTn_05.01.2016  #75m_CBCT_16.9.16_2Recon 
#42´´m_CBCT_1finFCTc_T0_27.05.2016 - 
#21´´f _CBCT_1FCTn_11.03.2016  #21´´f_CBCT_2FCTc_fin_29.03.2016, 
#21´L3R1m _CBCT_1FCTn_22.12.2015 - 
#3m_CBCT_1FCTc_I-300_14.03.2016  - 
#59m_CBCT_1FCTn_2X_23.12.2015  - 
#19´m_CTRL_1FCTn_16.02.2016  - 
#34´´f_CBCT_1FCTn_11.03.2016  - 
#87f_CBCT_1FCTn_29.01.2016  #87f_CBCT_19. 04.2016 
#96f_CBCT_1FCTn_11.03.2016  #96f_CBCT_FCT2n_fin_20.07.2016 
#92f_CBCT_1FCTn_29.01.2016  - 
#12´R1L0f_CBCT_1FCTn_17.12.2015  #12'R1L0f_CBCT_2FCTn_09.02.2015 
#7f_CBCT_1FCTn_17.12.15   #7f_CBCT_1FCTn_13.04.16  
#30´´f_CBCT_1FCTn_11.03.2016  - 
#11m_CTRL_1FCTn_08.01.2016  #11m_CTRL_2FCTc-I300,0,6ml_14.03.2016 
#35´´m_CTRL_1FCTn_08.01.2016  #35´´m_CTRL_2, finFCTn_15.7.16 
#57m_CTRL_1FCTn_23.12.2015  #57m_CTRL_2FCTc_06.04.2016 
#13´m _CTRL_1FCTn_29.12.2015  #13´m_CTRL_2FCTn_06.04.2016 
#62m_CTRL_1FCTn_28.12.2015  - 
#27´´m_CTRL_1fCTn_14.03.16  #27´´m_CTRL_1fCTn_4.4.16 
#40´´m_CTRL_1FCTn_14.03.2016  #40''m_CTRL_2FCTn_23.03.2016 
#8f_CTRL_1FCTn_17.12.2015   #8f_CTRL_2FCTn_01.03.2016 
#4´´f_CTRL_1FCTn_14.03.2016  #4f_CTRL_10.10.16_2 recons 
#94f_CTRL_1FCTn_14.03.2016  #94f_CTRL_2FCT_16.9.16 
#1´´f_CTRL_1FCTn_14.03.2016  - 
#20f_CTRL(CBCT)_2FCTc_15.06.2016 - 
#53´´f_VMAT24_20.4.2016   - 
#45´´f_VMAT24_13.4.2016   - 
#83f_CTRL_1FCTn_29.12.2015  - 
 
Abbreviations: rat identity and sex (e. g. #1´´f, number 1´´ female); m, male; VMAT, volumetric-
modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior; CBCT, cone-beam CT; CTRL 
corresponds to AN control group; 1FCT, first ‘Force CT’; fin, final; n, native; c contrast media; date of 







Rat data 3. (A) Rat identity and sex. (B) The organs affected by index tumors and additional tumors 
(asterisks represented). (C – J) Tumor entities (C, bone sarcoma; D, soft tissue sarcoma; E, lymphoma; 
F, malignant mesothelioma; G, carcinoma; H, breast cancer; I, brain tumor; and J, non-determined 
tumor). (K) Loss of Tp53+/C273X heterozygosity (LOH). (L) Ratio of the A/T peaks on the sequencing 
chromatogram (LOH determined by ≥ 2 times difference between A and T peaks). (M) Inflammation in 
tumor free lungs (graded by 0, none; 1, rare; 2, moderate; and 3, frequent).  
 
 
A B C D E F G H I J K L M 
91m Mediastinum to both lungs   1      − −  
65m Mediastinum/spine* 1*  1      LOH >2  
5m Spine to lungs 1        − −  
51''m Mediastinum    1     C273X 0,3  
46''m Mediastinum/chest wall right* 1*  1      − −  
15'f Mediastinum/spine*  1* 1       LOH >2  
28''f Mediastinum, lung, chest wall      1    C273X 1  
26''f Mediastinum  1       − −  
85f Chest wall left (rib)  1        − −  
88f Chest wall left (rib)  1        C273X 0,3  
14'f Mediastinum  1       − −  
50''m Mediastinum   1      − −  
41''m Mediastinum   1      C273X 1  
43''m Thymus and mediastinum   1      − −  
95f Mediastinum/spine*  1*  1      C273X 0,3  
33''f Bronchus, lung right      1    − −  
10f Axilla right  1       LOH 5  
43´´´m Mediastinum/lungs*   1  1*    LOH 3  
29´´m Mediastinum (esophagus)  1       − −  
64''f Mediastinum, mesothelia    1     LOH 5  
86''f Mediastinum   1      − −  
22´´m Mediastinum (thymus)   1      − −  
27´´´m Mediastinum   1      − −  
93''m Mediastinum/lung right*   1 1*      LOH 2,5  
99''m Sternum, lungs 1        LOH > 6  
24´´m Spine to lungs 1        − −  
82''f Mediastinum   1      C273X 2  
58''f Esophagus  1       C273X 0,3  
52´´f Esophagus  1       − −  
60''f Mediastinum     1    LOH 2  
81´´f Thorax, liver (fs)  1        LOH 5  
44´´f Back muscles  1       LOH 3  
79f Back muscles  1        −  
APPENDIX 
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38''m Dorsal muscle left  1       LOH >10  
48''m Abdomen        1  − 0 
20'm Pelvic region, bowel        1  −  
71f  Adrenal region right, kidney        1 C273X 0,2 1 
9f Abdomen, pelvis        1 C273X 0,2 2 
39''f Pelvic region        1  −  
16'm Pelvic region, prostate, bladder     1     − 0 
63m Femur/scapula bones* right (l. m.) 1        LOH 2,5  
69f Humerus bone right 1         − 0 
23''f Pelvis soft tissue     1    LOH 7 0 
18f lumbar spine bones 1         − 1 
89f Tailbone 1         −  
47´´f Skull bone 1         − 1 
37´´m Tailbone and soft tissue (l. m.)     1     − 1 
98''m Pelvic region        1 C273X 0,3 2 
31´´m Femur bone left/prostate* 1    1*     − 1 
42´´´m Femur bone left (l. m.), lungs 1    1*    C273X 0,3 0 
6´´f Hind-limb bone, left 1         − 2 
54''f Brain       1   − 1 
90''f Adrenal region right        1 C273X 1,6 1 
56''f Mammae, inguinal       1   C273X 0,2 2 
33´´´m Pelvic region and testes        1 C273X 0,3 0 
32´´m Pelvic region, prostate     1    C273X 0,3 2 
36´´m Hind limb bone (femur), left 1        LOH 2 1 
49''m Dorsal spine, muscles 1         − 2 
75m Overarm bone right 1         − 2 
42''m Bladder, pelvis      1    C273X -0,3 1 
21'm Femur, right 1        LOH 4  
3´ m Hind-limb bone, left, (l. m.) 1        LOH 4 0 
59m Hind-limb bone, left 1        LOH 3  
19f Tongue  1        − 1 
34''f Mandible, bone 1         − 2 
87f Brain       1   − 2 
96f Shoulder right, spine 1         − 2 
92f Pelvic region        1  − 0 
12'f Oviduct right        1 LOH 3 0 
7f Sacral bone, spine (l. m.) 1        LOH >10  
30''f Sacrum bone 1         − 2 
11m Jaw, right 1        LOH 3 2 
35''m Skull bone, pelvis* 1    1*     − 1 
57m Scapula, left 1        LOH >10 2 
13m Abdomen, chest wall, left        1  −  
62m Intestine, pelvis        1  − 1 
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27''m Pelvis, bowel        1  − 3 
40''m Abdomen, pelvis*    1* 1     − 3 
8f Brain       1   − 1 
2''f Skull bone  1         − 1 
4''f Mammae, inguinal left      1    − 1 
94f Mammae, both inguinal areas       1   C273X 0,4  
1''f Uterus, oviduct, left       1    LOH >2 0 
20f Abdomen/pancreas*    1* 1    C273X 1 0 
 
Abbreviations: rat identity and sex (e. g. #1´´f, number 1´´ female), m, male; C273X, heterozygous loss 









Additional tumors.   
 
Additional tumors Index tumor Volume Treatment 
BSA STSA BHDV-HDV VMAT 3×5 Gy 
BSA LY LDV VMAT 3×5 Gy 
BSA LY LDV VMAT 3×5 Gy 
BSA LY BHDV AP/PA 3×5 Gy 
LY STSA LDV-HDV AP/PA 3×8 Gy 
CA STSA BHDV VMAT 3×8 Gy 
CA BSA NIRV VMAT 3×8 Gy 
CA BSA NIRV VMAT 3×8 Gy 
CA BSA NIRV AN 0 Gy 
MM CA NIRV AN 0 Gy 
MM CA NIRV AN 0 Gy 
 
Abbreviations: BSA, bone sarcoma; LY, lymphoma; CA, carcinoma; MM, malignant mesothelioma; 
STSA, soft tissue sarcoma; HDV, high-dose volume; BHDV, bordering high-dose volume; HDV, high-
dose volume; VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior 
beams; AN, anesthesia controls; Gy, Gray; 3×5 Gy or 3×8 Gy, three fractions of 5 or 8 Gy. 
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Treatment body size and growth of rats. (a) The weight at the treatment of female and male rats was 
balanced between rats recruiting to VMAT or AP/PA groups (lines indicate the medians). (b) No notable 
difference in growth pattern between groups detected. Each dot represents the weight at every week of 
life. The lower and upper trails represent females or males respectively. The weight at treatment, weight 
increments and growth rates are given in Table A1, columns C – F.   



















Age at treatment and time to tumor. (a) The age at treatment was balanced between rats treated with 
VMAT and AP/PA, while most 3×8 Gy rats were by median 37.5 days older than rats from other groups 
(Table A1, column G). (b) Although the TTT in 3 × 8 Gy groups was simulative extended by 37.5 days, 
it remains significantly decreased for BHDV/HDV tumors. Mann-Whitney test. lines indicate the 
medians (see also Table M2).  
Abbreviations: AN, anesthesia only controls; CBCT, cone-beam computed tomography only controls; 
VMAT, volumetric-modulated arc therapy; AP/PA, anterior-posterior/posterior-anterior beams; Gy, 
Gray; TTT, time to tumor; NIRV, non-irradiated volume; LDV, low-dose volume; BHDV, bordering 
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p =  0 .5 2 p =  0 .3 6 p =  0 .4 1 p =  0 .8 5
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